

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification <sup>6</sup> : <b>C07H 21/04, C12N 15/00, C12Q 1/02, 1/68</b></p>	<p><b>A1</b></p>	<p>(11) International Publication Number: <b>WO 99/57130</b> (43) International Publication Date: 11 November 1999 (11.11.99)</p>
<p>(21) International Application Number: PCT/US99/09761 (22) International Filing Date: 5 May 1999 (05.05.99) (30) Priority Data: 60/084,329 5 May 1998 (05.05.98) US (71) Applicant (for all designated States except US): GENE LOGIC, INC. [US/US]; 708 Quince Orchard Road, Gaithersburg, MD 21046 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): PRASHAR, Yatindra [IN/US]; 9749 Clocktower Lane #304, Columbia, MD 21046 (US). WEISSMAN, Sherman [US/US]; 459 St. Ronan Street, New Haven, CT 06511 (US). (74) Agent: ADLER, Reid, G.; Morgan, Lewis &amp; Bockius LLP, 1800 M Street, N.W., Washington, DC 20036 (US).</p>		<p>(81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
<p>(54) Title: A PROCESS TO STUDY CHANGES IN GENE EXPRESSION IN T LYMPHOCYTES (57) Abstract  Methods are disclosed to identify T lymphocyte genes that are differentially expressed upon exposure to a pathogen (viral or bacterial), immunogen, antigen, or in a sterile inflammatory disease, autoimmune disease, immunodeficiency disease, lymphocytic cancers, or graft versus host rejection. The method involves the preparation of a gene expression profile of a T lymphocyte population exposed to a pathogen or isolated from a subject having one of the aforementioned pathologies and comparing that profile to a profile prepared from quiescent T lymphocytes. The present invention is particularly useful for identifying cytokine genes, genes encoding cell surface receptors and genes encoding intermediary signalling molecules. Related methods for identifying therapeutic or prophylactic immunomodulatory agents are presented. Articles of manufacture are disclosed that comprise selected grouping of nucleic acids, affixed to a solid support, that correspond to genes that are differentially expressed in various populations or subpopulations of T lymphocytes at variations stages of T cell differentiation, in quiescent versus activated T lymphocytes or normal versus diseased T lymphocytes.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

**A PROCESS TO STUDY CHANGES  
IN GENE EXPRESSION IN T LYMPHOCYTES**

**Inventors: Yatindra Prashar and Sherman Weissman**

This application is based on provisional application 60/084,329, filed May 5,  
5 1998, which is incorporated herein by reference in its entirety. This application is  
related to applications serial No. 08/510,032 and serial No. 08/688,514, both of which  
are herein incorporated by reference in their entirety. This application is also related  
to provisional applications serial No. 60/056,844 (Atty. Dkt. No. 044574-5003) and  
serial No. 60/056,861 (Atty. Dkt. No. 044574-5014) which are herein incorporated by  
10 reference in their entirety.

**Technical Field**

This invention relates to compositions and methods that are useful to identify  
agents that modulate the response of T lymphocytes (T cells) to a variety of foreign  
antigens and superantigens, and to modulate the role of T lymphocytes in immune  
15 deficiency diseases, cancer, tissue transplantation and immune disorders. The  
invention also relates to compositions and methods of identifying agents that  
modulate the differentiation of prothymocytes into specific T lymphocyte  
subpopulations.

20 **Background of the Invention**

The immune system is organized to solve the problems of rapid and specific  
recognition of an enormous number of potential antigens by cell-to-cell collaboration  
and by clonal expansion of cells specific for a given antigen. The immune response  
depends on T lymphocytes acting at various steps. One significant cell-to-cell  
25 collaboration in which T lymphocytes take part is the interaction between antigen  
presenting cells such as macrophages. Another significant cell-to-cell collaboration is  
between T lymphocytes (helper T lymphocytes) and antibody producing B cells. In

both of these collaborations, the ability of T lymphocytes to respond in an antigen-specific manner is central to the strategy of the immune system.

Besides recognizing foreign protein antigens, T lymphocytes also retain a functional memory of virtually all self-proteins which enables them to distinguish  
5 between self and nonself antigens. T lymphocytes are born in the bone marrow and mature in the thymus where they learn tolerance to self antigens. It is this ability to recognize self from nonself antigens that allow T lymphocytes to recognize and respond to potential invaders.

T lymphocytes are divided into subpopulations on the basis of function and  
10 phenotypic markers. Different T lymphocyte subpopulations function to help in antibody formation (T helper cells,  $T_H$ ), to kill target cells (T-cytotoxic cells,  $T_{CTL}$ ), to induce inflammation (T-delayed hypersensitivity cells,  $T_{DTH}$ ), and to inhibit immune responses (T-suppressor cells,  $T_S$ ). T helper cells are further divided into two major subpopulations:  $T_{H1}$  and  $T_{H2}$ .  $T_{H1}$  cells function primarily as helper cells for induction  
15 of B-cell proliferation and differentiation to IgG-producing plasma cells; whereas  $T_{H2}$  cells produce factors (e.g., interleukins) that induce B cells to differentiate and produce IgE and IgA.  $T_{H1}$  cells may further differentiate into  $T_{DTH}$  cells that are responsible for the inflammatory effects of T lymphocytes (e.g., delayed hypersensitivity, cytotoxicity) and secrete inflammatory mediators, such as  
20 lymphotoxin and interferon- $\gamma$  (IFN- $\gamma$ ).  $T_{H2}$  cell products may also stimulate differentiation of other white blood cells such as eosinophils and basophils.

T lymphocytes respond to antigen by cell activation and proliferation. This activation and proliferation coincides with a release of many effector molecules (e.g., interleukins) that activate or deactivate other lymphocytes, contribute to immune-  
25 mediated inflammation (lymphokines), or interact with other cell types. For instance, interleukins produced by  $T_H$  cells are required to induce activation and differentiation of B cells. At least 20 different interleukins have now been identified and are numbered from interleukin-1 (IL-1) to interleukin-20 (IL-20).  $T_{H1}$  cells produce IL-2, IFN- $\gamma$  and tumor necrosis factor in response to antigen stimulation, whereas  $T_{H2}$  cells  
30 synthesize IL-4, IL-5 and IL-6. Activation and differentiation of  $T_{CTL}$  cells result in

the appearance of cytoplasmic granules (secretory lysosomes). The T<sub>CTL</sub> granules contain perforin, granzymes, and proteoglycans that act to lyse or kill other cells. Therefore, the T lymphocyte population not only contains a variety of effector cells, but also is the master regulator of the immune system; the T lymphocyte is the  
5 director of the immunological orchestra of cells and proteins. T lymphocytes function to turn off or on other cells in the immune system via T suppressor cells, T helper cells and T contrasuppressor cells. STEWART SELL, IMMUNOLOGY, IMMUNOPATHOLOGY & IMMUNITY 30-33 (1996). T lymphocytes regulate (directly or indirectly) virtually all aspects of host immune resistance to infection, which include  
10 macrophage activity, antibody synthesis, synthesis of other inflammatory proteins, generation of inflammatory cells in the bone marrow and their recruitment into the circulation, and differentiation of other effector and regulatory lymphocytes.

The release of effector molecules and other changes in T lymphocytes during activation are preceded by changes in the expression levels of many genes. The  
15 regulation of expression levels of numerous T lymphocyte genes has been an area of extensive study (see Ullman *et al.*, (1990) *Ann. Rev. Immunol.*, 8: 421-452 and Kelly *et al.*, (1995) *Curr. Opin. Immunol.* 7: 327-332). The present inventor has utilized the analysis of differential gene expression on a more global level, as opposed to the analysis of the expression levels of individual RNA species, to provide simultaneous,  
20 near-quantitative information about the levels of gene expression for the multitude of genes whose expression levels are modulated during T lymphocyte activation.

### **Summary of the Invention**

While the role(s) of T lymphocytes and T lymphocyte subpopulations in cancer, infectious disease, and autoimmune and immunodeficiency disorders have  
25 been subject of intense study, the techniques of differential gene expression have not been exploited to identify therapeutic or prophylactic agents that modulate the response of T lymphocytes in these various roles. The present invention provides an approach to systematically assess the transcriptional response from lymphocytes activated through contact with a pathogen or from T lymphocytes isolated from a

subject with an infectious diseases, immune disorder, GVHD or neoplasm involving T lymphocytes.

One preferred embodiment relates to a method to identify a therapeutic or prophylactic agent that modulates the response of a T lymphocyte population to an antigen. This method comprises the steps of (1) preparing a first gene expression profile of a quiescent T lymphocyte population; (2) preparing a second gene expression profile of a T lymphocyte population exposed to the antigen; (3) treating the exposed T lymphocyte population with the agent; (4) preparing a third gene expression profile of the treated T lymphocyte population; (5) comparing the first, second and third gene expression profiles; and (6) identifying agents that modulate the response of a lymphocyte population to the antigen.

The invention also relates to a method to identify a therapeutic agent that modulates a T lymphocyte population found in a subject having a sterile inflammatory disease, autoimmune disorder, immunodeficiency disease, cancer or graft-versus-host disease (GVHD). This method comprises the steps of: (1) preparing a first gene expression profile of a T lymphocyte population in a subject having the sterile inflammatory disease, autoimmune disorder, immunodeficiency disease, cancer, or GVHD; (2) treating the T lymphocyte population with the agent; (3) preparing a second gene expression profile of the treated T lymphocyte population; (4) comparing the first and second gene expression profiles with a gene expression profile of a normal T lymphocyte population; and (5) identifying an agent that modulates a T lymphocyte population found in a subject having a sterile inflammatory disease, autoimmune disorder, immunodeficiency disease, cancer, or GVHD.

In yet another aspect, the present invention relates to a method of diagnosing a sterile inflammatory disease, autoimmune disorder, immunodeficiency disease, cancer, or GVHD in a subject. The method comprises the steps of: (1) preparing a first gene expression profile of a T lymphocyte population from the subject; (2) comparing the first gene expression profile to at least one second gene expression profile from a T lymphocyte population from a subject having a sterile inflammatory disease, autoimmune disorder, immunodeficiency disease, cancer, or GVHD and to a

third gene expression profile of a normal T lymphocyte population; and (3) determining if the subject has a sterile inflammatory disease, autoimmune disorder, immunodeficiency disease, cancer, or GVHD.

Another aspect of the present invention relates to a method of identifying therapeutic or prophylactic compounds that modulate a T lymphocyte population that arises from a genetic defect or mutation. This method comprises the steps of: (1) preparing a first gene expression profile of a T lymphocyte population that arises from the genetic defect; (2) treating the first T lymphocyte population with the agent; (3) preparing a second gene expression profile of the treated T lymphocyte population; (4) comparing the first and second gene expression profiles with a gene expression profile of a normal T lymphocyte population; and (5) identifying agents that modulate a T lymphocyte population that arises from a genetic defect.

In contemplated variations of the foregoing methods, relevant data from, *e.g.*, the first or second (or third) gene expression profile (*e.g.*, as shown by the positions and intensities of bands on a gel or the quantity, intensity and relative elution position from a column) may be compared with corresponding relevant data with data that has been stored in an electronic or computer-readable format. For example, a data base of the gene expression profile of quiescent T cells may be used to compare the gene expression profile of T cells that have been activated by exposure to any particular antigen. Similarly, a gene expression profile of a T cell population exposed to an agent that is being evaluated as a candidate agent to modulates the response of a T lymphocyte population to an antigen can be compared to a data base of the gene expression characteristics of a gene expression profile of a T lymphocyte population exposed to that antigen.

Thus, the present invention also relates to a method to identify a therapeutic or prophylactic agent that modulates the response of a T lymphocyte population to an antigen, comprising the steps of: (1) preparing a first gene expression profile of a T lymphocyte population exposed to the antigen; (2) treating the exposed T lymphocyte population with the agent; (3) preparing a third gene expression profile of the treated T lymphocyte population; (4) comparing the first and second gene expression profiles

with a data base containing the corresponding gene expression profile information from a quiescent T lymphocyte population not contacted with the antigen; and (6) identifying agents that modulate the response of a lymphocyte population to the antigen.

- 5           The present invention also relates to a method to identify a therapeutic or prophylactic agent that modulates the response of a T lymphocyte population to an antigen, comprising the steps of: (1) preparing a first gene expression profile from a T lymphocyte population that has been exposed to the antigen and with the candidate therapeutic or prophylactic agent; and (2) comparing the first gene expression profile
- 10 with a data base containing the corresponding gene expression profile information from a quiescent T lymphocyte population not contacted with the antigen and, as appropriate, also comparing the first gene expression profile with the corresponding gene expression profile information from a T lymphocyte population that was contacted with the antigen but not contacted with the candidate therapeutic or
- 15 prophylactic agent; and (3) identifying agents that modulate the response of a lymphocyte population to the antigen.

In a similar fashion, it is contemplated that the gene expression profile information from the "first" gene expression profiles in the methods summarized above, *i.e.*, from quiescent or from diseased but untreated T lymphocyte populations,

20 can reside in a data base to which the gene expression profile information of the "second" gene expression profile may be compared.

Such data bases also reflect another aspect of the present invention and these data bases may contain data based on one or more separately prepared profiles and further may reflect averaged or normalized or otherwise manipulated information.

25 When comparisons are made using data that reflects the average of separately prepared profiles, an average prepared from two separate profiles is preferred, more preferably from three or four such profiles, and most preferably from five or more such profiles. One skilled in the art will know how to prepare and manipulate the information in such data bases in order to maximize the practical value of the data

30 contained therein.



-7-

In an article of manufacture aspect, the present invention relates to a grouping of nucleic acids affixed to a solid support, said nucleic acids preferably represent the genes or fragments of genes (or corresponding cDNAs or RNAs) whose expression levels are modulated in a T lymphocyte population that arises, *e.g.*, from exposure to an antigen; are modulated in a T lymphocyte population found in a subject having a sterile inflammatory disease, autoimmune disorder, immunodeficiency disease, cancer, or GVHD; or are modulated in a T lymphocyte population arising from a genetic defect.

In yet another aspect, the present invention relates to an isolated nucleic acid molecule comprising the structure: R-X-R', wherein X is the novel DNA sequence (or corresponding RNA sequence) or novel portions thereof as identified in SEQ ID NOS. 16, 22, 24, 25, 31, 33 or 34; and wherein R and R' are sequences contiguous with X in nucleic acid fragments which specifically hybridize with X.

#### **Brief Description of the Drawings**

Figure 1 presents autoradiograms of the expression profiles generated from cDNAs made with RNA isolated from quiescent Jurkat cells treated with either 12-O-tetradecanoylphorbol-13-acetate (TPA) and phytohemagglutinin (PHA) or ionomycin and TPA.

Primer Set	Lanes	Primer	N1	N2
1	1, 2	8.3	A	C
2	3, 4	8.4	C	T
3	5, 6	8.5	G	C
4	7, 8	8.6	C	C
5	9, 10	9.2	G	A
6	11, 12	9.3	A	A
7	13, 14	9.4	C	G
8	15, 16	9.5	A	T
9	17, 18	10.2	A	G

-8-

Primer Set	Lanes	Primer	N1	N2
10	19, 20	10.3	C	A
11	21, 22	10.4	G	G
12	23, 24	10.5	G	T

- 5 (A) All possible 12 anchoring oligo d(T<sub>18</sub>)n1, n2 were used to generate a complete expression profile for the restriction enzyme *Bgl* II. Expression profiles were also generated, and yielded analogous results, using all possible 12 anchoring oligo d(T<sub>18</sub>)n1, n2 for each of the following restriction enzymes: *Xba*II, *Spe*I, *Nco*I, *Hind* III, *Bam*HI and *Xba*I. (B) Figure 1B is an autoradiogram of dilutions using RP 8.6
- 10 wherein the cDNAs have been digested with *Hind* III.

Figure 2 is a three dimensional and generalized graphical representation of gene expression in (a) quiescent T lymphocytes; (b) gene expression in activated T lymphocytes; and (c) the differences in gene expression between quiescent and activated T lymphocytes.

- 15 Figure 3 represents quantitative differences of specific cDNA bands from display gels of quiescent versus activated T lymphocytes (Jurkat cells). Clone TA1 (SEQ ID NO.1) JkA1 (SEQ ID NO.2) TA1 (SEQ ID NO.1) JkA2 (SEQ ID NO.3), JkA3 (SEQ ID NO.4) JkA4 (SEQ ID NO.5) JkA5 (SEQ ID NO.6) JkA6 (SEQ ID NO.7) JkA7 (SEQ ID NO.8) JkA8 (SEQ ID NO.9) JkA9 (SEQ ID NO.10) JkA10
- 20 (SEQ ID NO.11) JkA11 (SEQ ID NO.12) JkR1 (SEQ ID NO.13)
- In each panel, the left lane is a cDNA band from untreated T lymphocytes and the right lane is the corresponding cDNA band from activated T lymphocytes. In panel 7 (not panel 7(a)), peripheral blood T lymphocyte RNA was used for RT-PCR.

- Figure 4 is a table of the cDNA bands of Figure 3 that correspond to mRNA
- 25 species that are differentially expressed in the quiescent Jurkat cells and in activated Jurkat cells.

Figure 5 presents summary data for mRNAs that are differentially expressed in activated versus quiescent T cells and the identity of cDNAs corresponding to said mRNAs. Although not represented in the figure, the inventors have identified yet another sequence (SEQ ID NO.34) that corresponds to a differentially expressed mRNA.

### **Modes of Carrying Out the Invention**

#### **General Description**

The response of T lymphocytes to antigens, superantigens, allografts and xenografts, T lymphocyte function in autoimmune and immunodeficiency disorders, as well as T lymphocyte neoplasms, is a subject of primary importance in view of the need to find ways to modulate the immune response. Similarly, the response of T lymphocytes to agonists (pro-inflammatory molecules), such as IL-2, is a subject of great importance in view of the need to find better methods of controlling inflammation brought about by various disease states.

One means of assessing the response of T lymphocytes to antigens, as well as determining differences between diseased lymphocytes versus normal, is to measure the ability of T lymphocytes to synthesize specific RNA *de novo* either upon contact with an antigen, allergen or pathogen or the state of RNA message in T lymphocytes found in different T lymphocyte disorders.

The following discussion presents a general description of the invention as well definitions for certain terms used herein.

#### **Definitions**

As used herein, "T lymphocyte population", also referred to as a "T cell population", refers to any population of T lymphocytes obtained from a variety of sources, such as mammalian (*e.g.*, human) spleen, tonsils and peripheral blood. See Lewis *et al.*, (1988) *Proc. Natl. Acad. Sci.*, 85: 9743-9747. T-cell clones, such as a Jurkat cell line, may also be used. Such T lymphocyte clones are numerous and

commonly available (see *Research Monographs in Immunology*, eds. von Doehmer, H. and Haaf, V.; Section D: "Human T-Cell Clones", vol. 8, pgs. 243-333; Elsevier Science Publishers, N.Y.[1985]).

As used herein, "quiescent T lymphocytes" refers to resting T lymphocytes  
5 that have not been activated by exposure to an activating agent, pathogen, mitogen, immunogen, allergen, antigen or superantigen or any other agent that induces a change in T lymphocyte mRNA expression.

As used herein, "activated T lymphocytes" refers to T lymphocytes which  
have been exposed to an activating agent, pathogen, mitogen, immunogen, allergen,  
10 antigen, superantigen or any other agent that induces a change in T lymphocyte mRNA expression.

As used herein, "T<sub>H1</sub>" refers to the subpopulation of T helper cells which secrete IL-2 and interferon  $\gamma$  (IFN- $\gamma$ ), but not IL-4. T<sub>H1</sub> cells also secrete IL-3 and granulocyte-monocyte colony-stimulating factor (GM-CSF).

As used herein, "T<sub>H2</sub>" refers to the subpopulation of T helper cells which  
15 secrete IL-4, IL-5, but not IL-2 or IFN- $\gamma$ . T<sub>H2</sub> cells also secrete IL-3 and granulocyte-monocyte colony-stimulating factor (GM-CSF).

As used herein, "T<sub>DTH</sub>" refers to the subpopulation of T lymphocytes that initiate delayed hypersensitivity reactions and express, amongst others, the following  
20 markers: TCR, CD4, IL-2, and IL-3.

As used herein, T<sub>CTL</sub> refers to the subpopulation of T lymphocytes that lyse specific target cells. T<sub>CTL</sub> cells express amongst other markers: TCR and CD8.

As used herein, T<sub>s</sub> refers to the subpopulation of T cells that suppress immune responses; these cell express amongst other markers: TCR and CD8.

As used herein, "cortical T cells" refers to T cells which express CD7, CD5,  
25 CD2, and CD38.

As used herein, "medullary T cells" refers to T cells which express CD1, CD3, CD4, CD8, CD5, CD2, CD7 and CD38.

As used herein, "peripheral T lymphocytes" refers to T lymphocytes which circulate through the blood and other non-thymus lymphoid organs and express either CD4 or CD8.

As used herein, "NK cells" refers to a class of lymphocytes that do not bear markers for either T lymphocytes or B cells, but includes natural killer (NK) cells. "NK cells" express amongst other markers FcR, CD16, perforins and granzymes.

As used herein, "TIL cells" refers to tumor infiltrating lymphocytes extracted from tumor tissue.

As used herein, "LAK cells" refers to lymphokine activated killer cells that do not bear T lymphocyte markers, are not MHC restricted, lyse cell lines resistant to natural killer (NK) cell killing, and are effective in reducing large tumor cell masses in mice. STEWART SELL, 919 (1996).

As used herein, the term "antigen" refers to a substance that elicits an immune response and can include superantigens.

As used herein, the term "sterile inflammatory disease" refers to any inflammatory disease caused by immune or non-immune mechanisms not directly linked to infection (see STEWART SELL *ET AL.*, 1996). Examples of sterile inflammatory diseases include, but are not limited to psoriasis, rheumatoid arthritis, glomerulonephritis, asthma, cardiac and renal reperfusion injury, thrombosis, adult respiratory distress syndrome, inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis and periodontal disease.

As used herein, the term "mitogen" refers to a class of substances that stimulate lymphocytes to proliferate independently of antigen.

As used herein, the term "superantigen" refers to a special class of antigens, defined by their capacity to stimulate a large fraction of T lymphocytes. Superantigens include several "enterotoxins", which are globular proteins released by such bacteria as *Staphylococcus aureus*.

As used herein, the term "pathogen" refers to any infectious organism including bacteria, viruses, parasites, mycoplasma, protozoans, and fungi (including molds and yeast). "Pathogenic bacteria" include, but are not limited to *Staphylococci*

- (*e.g., aureus*), *Streptococci* (*e.g., pneumoniae*), *Clostridia* (*e.g., perfringens*), *Neisseria* (*e.g., gonorrhoeae*), *Enterobacteriaceae* (*e.g., E. coli* as well as *Klebsiella*, *Salmonella*, *Shigella*, *Yersinia* and *Proteus*), *Helicobacter* (*e.g., pylori*), *Vibrio* (*e.g., cholerae*), *Campylobacter* (*e.g., jejuni*), *Pseudomonas* (*e.g., aeruginosa*),
- 5 *Haemophilus* (*e.g., influenzae*), *Bordetella* (*e.g., pertussis*), *Mycoplasma* (*e.g., pneumoniae*), *Ureaplasma* (*e.g., urealyticum*), *Legionella* (*e.g., pneumophila*), *Spirochetes* (*e.g., Treponema, Leptospira* and *Borrelia*), *Mycobacteria* (*e.g., tuberculosis, smegmatis*), *Actinomyces* (*e.g., israelii*), *Nocardia* (*e.g., asteroides*), *Chlamydia* (*e.g., trachomatis*), *Rickettsia*, *Coxiella*, *Ehrlichia*, *Rochalimaea*,
- 10 *Brucella*, *Yersinia*, *Francisella*, *Mycobacterium leprae*, and *Pasteurella*.

- "Pathogenic viruses" include amongst others: human T lymphocyte virus type I and II (HTLV-I and HTLV-II), Epstein-Barr Virus (EBV), group C adenoviruses, herpes simplex virus, cytomegalovirus, poliovirus, rubella, measles, mumps respiratory syncytial virus (RSV), vesicular stomatitis virus (VSV), HIV-1, rabies
- 15 virus, influenza A, parainfluenza, and lymphocytic choriomeningitis virus.

- As used herein, "immunodeficiency diseases" or "immunodeficiency disorders" include both acquired immunodeficiency and primary immunodeficiency disorders. Primary immunodeficiency disorders encompass: antibody deficiency disorders (*e.g., sex linked agammaglobulinemia, common variable*
- 20 *immunodeficiency, selective IgA deficiency, immunodeficiency with elevated IgM, transient hypogammaglobulinemia of infancy, antibody deficiency with near normal immunoglobulins, and X-linked lymphoproliferative disease*); cellular immunodeficiency disorders (*e.g., thymic hypoplasia, and Nezelof's syndrome*); and severe combined immunodeficiency (SCID) disorders (*e.g., autosomal recessive*
- 25 *severe combined immunodeficiency disease, X-linked recessive severe combined immunodeficiency disease, defective expression of major histocompatibility complex antigens, and severe combined immunodeficiency with leukopenia*).

The phrase "solid support" refers to any support to which nucleic acids can be bound or immobilized, including nitrocellulose, nylon, glass, other solid supports

which are positively charged, including nanochannel glass arrays disclosed by Beattie (WO95/1175).

The phrase "specifically hybridizes" refers to nucleic acids which hybridize under highly stringent or moderately stringent conditions to the nucleic acids  
5 containing at least one of the sequences identified in the Figures. In referencing the Figures, we mean at all points the Figures and the discussion of the Figures found in the Brief Description of Drawings. Preferably such specifically hybridizing nucleic acids will present a clear and detectable signal, and they may be labeled by various means that are known to those skilled in the art.

10 The phrase "isolated nucleic acid" refers to nucleic acids that have been separated from contaminant nucleic acids encoding other polypeptides. "Nucleic acids" refers to all forms of DNA and RNA, including cDNA molecules and antisense RNA molecules.

The phrase "sequences contiguous with" refers to sequences which are  
15 covalently linked to a given nucleic acid sequence or fragment at either the 5' or 3' end through phospho-diester bonds. Such contiguous sequences are contained within a single molecule with a given nucleic acid sequence or fragment, such as a cDNA molecule.

The phrase "gene expression profile", also referred to as a "differential  
20 expression profile" or "expression profile", refers to a representation of the expression of mRNA species in a cell sample or population. For instance, a gene expression profile can refer to an autoradiograph of labeled cDNA fragments produced from total cellular mRNA separated on the basis of size by known procedures. Such procedures include slab gel electrophoresis, capillary gel electrophoresis, high performance liquid  
25 chromatography (HPLC), and the like. Digitized representations of scanned electrophoresis gels are also included as are two and three dimensional representations of the digitized data.

While a gene expression profile encompasses a representation of the expression level of at least one mRNA species, in practice, the typical gene expression  
30 profile represents the expression level of multiple mRNA species. For instance, a

gene expression profile useful in the methods and compositions disclosed herein represents the expression levels of at least about 1, 5, 10, 20, 50, 100, 150, 200, 300, 500, 1000, 10,000, 50,000 or, more preferably, substantially all of the detectable mRNA species in a cell sample or population. Particularly preferred are gene  
5 expression profiles or arrays affixed to a solid support that contain a representative number of mRNA species, whose expression levels are modulated under the relevant infection, disease, screening, treatment or other experimental conditions. In some instances, a sufficient representative number of such mRNA species will be at least about 1, 2, 5, 10, 15, 20, 25, 30, 40, 50, 50-75 or 100. The expression profiles  
10 preferably will also be able to quantitatively differentiate the relative quantities of mRNA species in a cell.

Gene expression profiles can be produced by any means known in the art, including, but not limited to the methods disclosed by: Liang *et al.*, (1992) *Science* 257: 967-971; Ivanova *et al.*, (1995) *Nucleic Acids Res.* 23: 2954-2958; Guilfoyl *et al.*, (1997) *Nucleic Acids Res.* 25(9): 1854-1858; Chee *et al.*, (1996) *Science* 274: 610-614; Velculescu *et al.*, (1995) *Science* 270: 484-487; Fischer *et al.*, (1995) *Proc. Natl. Acad. Sci. USA* 92(12): 5331-5335; and Kato, (1995) *Nucleic Acids Res.* 23(18): 3685-3690. Gene expression profiles also may be produced by the methods of Belyavsky *et al.*, in U.S. Patent Application Serial No. 08/499,899. Preferably, gene  
20 expression profiles are produced by the methods of Prashar *et al.*, (WO 97/05286) and Prashar *et al.*, (1996) *Proc. Natl. Acad. Sci. USA* 93: 659-663.

As an example, gene expression profiles as described herein are made to identify one or more genes whose expression levels are modulated in a T lymphocyte population exposed to a pathogen, allergen, antigen, mitogen or superantigen, or a T  
25 lymphocyte population isolated, for example, from a subject having a sterile inflammatory disease, GVHD or cancer. The assaying of the modulation of gene expression via the production of a gene expression profile generally involves the production of cDNA from polyA RNA (mRNA) isolated from T lymphocytes as described below.



The mRNAs are isolated from a T lymphocyte source (*e.g.*, prothymocytes or T<sub>H2</sub> cells). The cells may be obtained from an *in vivo* source, such as a peripheral blood or thymus. As is apparent to one skilled in the art, any lymphocyte type (*e.g.*, plasma cells, B cells, T lymphocytes or T lymphocyte subpopulations) may be used, however, T lymphocytes are preferred. Furthermore, the peripheral blood cells that are initially obtained may be subjected to various separation techniques (*e.g.*, flow cytometry, density gradients) to purify specific T lymphocyte subpopulations (*e.g.*, T<sub>DTH</sub>, T<sub>CTL</sub>, T<sub>H2</sub>, etc.).

"mRNAs" are isolated from cells by any one of a variety of techniques.

10 Numerous techniques are well known (see *e.g.*, SAMBROOK *ET AL.*, MOLECULAR CLONING: A LABORATORY APPROACH, Cold Spring Harbor Press, NY, (1987); AUSUBEL *ET AL.*, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, Greene Publishing Co. NY, (1995)). In general, these techniques first lyse the cells and then enrich for or purify RNA. In one such protocol, cells are lysed in a Tris-buffered solution  
15 containing sodium dodecyl sulfate. The lysate is extracted with phenol/chloroform, and nucleic acids are precipitated. Purification of poly(A)-containing RNA is not a requirement. The mRNAs may, however, be purified from crude preparations of nucleic acids or from total RNA by chromatography, such as binding and elution from oligo(dT)-cellulose or poly(U)-Sephadex®. As stated above, other protocols and  
20 methods for isolation of RNAs may be substituted.

The mRNAs are reverse transcribed using an RNA-directed DNA polymerase, such as "reverse transcriptase" isolated from such retroviruses as AMV, MoMuLV or recombinantly produced. Many commercial sources of enzyme are available (*e.g.*, Pharmacia, New England Biolabs, Stratagene Cloning Systems). Suitable buffers,  
25 cofactors, and conditions are well known and supplied by various manufacturers (see also, SAMBROOK *ET AL.*, (1989) *supra*; AUSUBEL *ET AL.*, (1995) *supra*).

Various oligonucleotides are used in the production of cDNA. In particular, the methods described herein utilize oligonucleotide primers for cDNA synthesis, and adapters, and primers for amplification. Oligonucleotides are generally synthesized as  
30 single strands by standard chemistry techniques, including automated synthesis.

Oligonucleotides are subsequently de-protected and may be purified by precipitation with ethanol, chromatographed using a sized or reversed-phase column, denaturing polyacrylamide gel electrophoresis, high-pressure liquid chromatography (HPLC), or other suitable method. In addition, within certain preferred embodiments, a functional group, such as biotin, is incorporated preferably at the 5' or 3' terminal nucleotide. A biotinylated oligonucleotide may be synthesized using pre-coupled nucleotides, or alternatively, biotin may be conjugated to the oligonucleotide using standard chemical reactions known to individuals skilled in the art. Other functional groups, such as fluorescent dyes, radioactive molecules, digoxigenin, and the like, may also be used.

Partially-double stranded adaptors are formed from single-stranded oligonucleotides by annealing complementary single-stranded oligonucleotides that are chemically synthesized or by enzymatic synthesis. Following synthesis of each strand, the two oligonucleotide strands are mixed together in a buffered salt solution (e.g., 1 M NaCl; 100 mM Tris-HCl, pH 8.0; 10 mM EDTA) or in a buffered solution containing  $Mg^{+2}$  (e.g., 10 mM  $MgCl_2$ ) and annealed by heating to high temperature and slow cooling to room temperature.

The oligonucleotide primer that primes first strand DNA synthesis comprises a 5' sequence incapable of hybridizing to a polyA tail of the mRNAs, and a 3' sequence that hybridizes to a portion of the polyA tail of the mRNAs and at least one non-polyA nucleotide immediately upstream of the polyA tail. The 5' sequence is preferably of a sufficient length such that can serve as a primer for amplification. The 5' sequence also preferably has an average G+C content and does not contain large palindromic sequences; certain palindromes, such as a recognition sequence for a restriction enzyme, may be acceptable. Examples of suitable 5' sequences are CTCTCAAGGATC:TACCGCT (SEQ ID NO.35), CAGGGTAGACGACGCTACGC (SEQ ID NO.36), and TAATACCGCGCCACATAGCA (SEQ ID NO.37).

The 5' sequence is joined to a 3' sequence comprising a sequence that hybridizes to a portion of the polyA tail of mRNAs and at least one non-polyA nucleotide immediately upstream. Although the polyA-hybridizing sequence is typically a homopolymer of dT or dU, it need only contain a sufficient number of dT

or dU bases to hybridize to polyA under the conditions employed. Both oligo-dT and oligo-dU primers have been used and give comparable results. Thus, other bases may be interspersed or concentrated, as long as hybridization is not impeded. Typically, 12 to 18 bases or 12 to 30 bases of dT or dU will be used. However, as one skilled in the art appreciates, the length need only be sufficient to obtain hybridization. The non-polyA nucleotides are A, C, or G, or a nucleotide derivative, such as inosinate. If one non-polyA nucleotide is used, then three oligonucleotide primers are needed to hybridize to all mRNAs. If two non-polyA nucleotides are used, then 12 primers are needed to hybridize to all mRNAs (AA, AC, AG, AT, CA, CC, CG, CT, GA, GC, GG, GT). If three non-poly A nucleotides are used, then 48 primers are needed (3 X 4 X 4). Although there is no theoretical upper limit on the number of non-polyA nucleotides, practical considerations make the use of one or two non-polyA nucleotides preferable.

For cDNA synthesis, the mRNAs are either subdivided into three (if one non-polyA nucleotide is used) or twelve (if two non-polyA nucleotides are used) fractions, each containing a single oligonucleotide primer, or the primers may be pooled and contacted with a mRNA preparation. Other subdivisions may alternatively be used. Briefly, first strand cDNA is initiated from the oligonucleotide primer by reverse transcriptase (RTase). As noted above, RTase may be obtained from numerous sources and protocols are well known. Second strand synthesis may be performed by RTase (Gubler and Hoffman, *Gene* 25: 263, 1983), which also has a DNA-directed DNA polymerase activity, with or without a specific primer, by DNA polymerase 1 in conjunction with RNaseH and DNA ligase, or other equivalent methods. The double-stranded cDNA is generally treated with phenol:chloroform extraction and ethanol precipitation to remove protein and free nucleotides.

Double-stranded cDNA is subsequently digested with an agent that cleaves in a sequence-specific manner. Such cleaving agents include restriction enzymes. Restriction enzyme digestion is preferred; enzymes that are relatively infrequent cutters (*e.g.*,  $\geq 5$  bp recognition site) are more preferred, and those that leave overhanging ends are especially preferred. A restriction enzyme with a six base pair

recognition site cuts approximately 8% of cDNAs, so that approximately 12 such restriction enzymes should be needed to digest every cDNA at least once. By using 30 restriction enzymes, digestion of every cDNA is assured.

The adapters for use in the present invention are designed such that the two  
5 strands are only partially complementary and only one of the nucleic acid strands that the adapter is ligated to can be amplified. Thus, the adapter is partially double-stranded (*i.e.*, comprising two partially hybridized nucleic acid strands), wherein portions of the two strands are non-complementary to each other and portions of the two strands are complementary to each other. Conceptually, the adapter is “Y-  
10 shaped” or “bubble-shaped.” When the 5' region is non-paired, the 3' end of other strand cannot be extended by a polymerase to make a complementary copy. The ligated adapter can also be blocked at the 3' end to eliminate extension during subsequent amplifications. Blocking groups include dideoxynucleotides or any other agent capable of blocking the 3'-OH. In this type of adapter (“Y-shaped”), the non-  
15 complementary portion of the upper strand of the adapters is preferably a length that can serve as a primer for amplification. As noted above, the non-complementary portion of the lower strand need only be one base, however, a longer sequence is preferable (*e.g.*, 3 to 20 bases; 3 to 15 bases; 5 to 15 bases; or 14 to 24 bases). The complementary portion of the adapter should be long enough to form a duplex under  
20 conditions of ligation.

For “bubble-shaped” adapters, the non-complementary portion of the upper strands is preferably a length that can serve as a primer for amplification. Thus, this portion is preferably 15 to 30 bases. Alternatively, the adapter can have a structure similar to the Y-shaped adapter, but has a 3' end that contains a moiety that a DNA  
25 polymerase cannot extend from.

Amplification primers are also used in the present invention. Two different amplification steps are performed in the preferred aspect. In the first, the 3' end (referenced to mRNA) of double stranded cDNA that has been cleaved and ligated with an adapter is amplified. For this amplification, either a single primer or a primer  
30 pair is used. The sequence of the single primer comprises at least a portion of the 5'

sequence of the oligonucleotide primer used for first strand cDNA synthesis. The portion need only be long enough to serve as an amplification primer. The primer pair consists of a first primer whose sequence comprises at least a portion of the 5' sequence of the oligonucleotide primer as described above; and a second primer  
5 whose sequence comprises at least a portion of the sequence of one strand of the adapter in the non-complementary portion. The primer will generally contain all the sequence of the non-complementary portion, but may contain less of the sequence, especially when the non-complementary portion is very long, or more of the sequence, especially when the non-complementary portion is very short. In some embodiments,  
10 the primer will contain a sequence of the complementary portion, as long as that sequence does not appreciably hybridize to the other strand of the adapter under the amplification conditions employed. For example, in one embodiment, the primer sequence comprises four bases of the complementary region to yield a 19 base primer, and amplification cycles are performed at 56°C (annealing temperature), 72°C  
15 (extension temperature), and 94°C (denaturation temperature). In another embodiment, the primer is 25 bases long and has 10 bases of sequence in the complementary portion. Amplification cycles for this primer are performed at 68°C (annealing and extension temperature) and 94°C (denaturation temperature). By using these longer primers, the specificity of priming is increased.

20 The design of the amplification primers will generally follow well-known guidelines, such as average G-C content, absence of hairpin structures, inability to form primer-dimers and the like. At times, however, it will be recognized to those skilled in the art that deviations from such guidelines may be appropriate or desirable.

After amplification, the lengths of the amplified fragments are determined.

25 Any procedure that separate nucleic acids on the basis of size and allows detection or identification of the nucleic acids is acceptable. Such procedures include slab gel electrophoresis, capillary gel electrophoresis, high performance liquid chromatography (HPLC), and the like.

Electrophoresis is technique based on the mobility of DNA in an electric field.

30 Negatively charged DNA migrates towards a positive electrode at a rate dependent on

its total charge, size, and shape. Most often, DNA is electrophoresed in agarose or polyacrylamide gels. For maximal resolution, polyacrylamide is preferred and for maximal linearity, a denaturant, such as urea is present. A typical gel setup uses a 19:1 mixture of acrylamide:bisacrylamide and a Tris-borate buffer. DNA samples are  
5 denatured and applied to the gel, which is usually sandwiched between glass plates. A typical procedure can be found in SAMBROOK *ET AL.*, (1989) or AUSUBEL *ET AL.*, (1995). Variations may be substituted as long as sufficient resolution is obtained.

Capillary electrophoresis, (CE) in its various manifestations (*e.g.*, free solution, isotachopheresis, isoelectric focusing, polyacrylamide gel, micellar  
10 electrokinetic "chromatography"), allows high resolution separation of very small sample volumes. Briefly, in capillary electrophoresis, a neutral coated capillary, such as a 50  $\mu$ m X 37 cm column (eCAP neutral, Beckman Instruments, CA), is filled with a linear polyacrylamide (*e.g.*, 0.2% polyacrylamide), a sample is introduced by high-pressure injection followed by an injection of running buffer (*e.g.*, 1X TBE). The  
15 sample is electrophoresed and fragments are detected. An order of magnitude increase can be achieved with the use of capillary electrophoresis. Capillaries may be used in parallel for increased throughput (Smith *et al.*, (1990) *Nuc. Acids. Res.* 18: 4417; Mathies and Huang, (1992) *Nature* 359: 167). Because of the small sample volume that can be loaded onto a capillary, the sample may be concentrated to  
20 increase the level of detection. One means of concentration is sample stacking (Chien and Burgi, (1992) *Anal. Chem.* 64: 489A). In sample stacking, a large volume of sample in a low concentration buffer is introduced to the capillary column. The capillary is then filled with a buffer of the same composition, but at higher concentration, such that when the sample ions reach the capillary buffer with a lower  
25 electric field, they stack into a concentrated zone. Sample stacking can increase detection by one to three orders of magnitude. Other methods of concentration, such as isotachopheresis, may also be used.

High-performance liquid chromatography (HPLC) is a chromatographic separation technique that separates compounds in solution. HPLC instruments consist  
30 of a reservoir of mobile phase, a pump, an injector, a separation column, and a

detector. Compounds are separated by injecting an aliquot of the sample mixture onto the column. The different components in the mixture pass through the column at different rates due to differences in their partitioning behavior between the mobile liquid phase and the stationary phase. IP-RO-HPLC on non-porous PS/DVB particles  
5 with chemically bonded alkyl chains can also be used to analyze nucleic acid molecules on the basis of size (Huber *et al.*, (1993) *Anal. Biochem.* 121: 351; Huber *et al.*, (1993) *Nuc. Acids Res.* 21: 1061; Huber *et al.*, (1993) *Biotechniques* 16: 898).

In each of these analysis techniques, the amplified fragments are detected. A variety of labels can be used to assist in detection. Such labels include, but are not  
10 limited to, radioactive molecules (*e.g.*,  $^{35}\text{S}$ ,  $^{32}\text{P}$ ,  $^{33}\text{P}$ ), fluorescent molecules, and mass spectrometric tags. The labels may be attached to the oligonucleotide primers or to nucleotides that are incorporated during DNA synthesis, including amplification.

Radioactive nucleotides may be obtained from commercial sources; radioactive primers may be readily generated by transfer of label from  $\gamma$ - $^{32}\text{P}$ -ATP to a  
15 5'-OH group by a kinase (*e.g.*, T4 polynucleotide kinase). Detection systems include autoradiograph, phosphor image analysis and the like.

Fluorescent nucleotides may be obtained from commercial sources (*e.g.*, ABI, Foster City, CA) or generated by chemical reaction using appropriately derivatized dyes. Oligonucleotide primers can be labeled, for example, using succinimidyl esters  
20 to conjugate to amine-modified oligonucleotides. A variety of fluorescent dyes may be used, including 6 carboxyfluorescein, other carboxyfluorescein derivatives, carboxyrhodamine derivatives, Texas red derivatives, and the like. Detection systems include photomultiplier tubes with appropriate wave-length filters for the dyes used. DNA sequence analysis systems, such as produced by ABI (Foster City, CA), may  
25 also be used.

After separation of the amplified cDNA fragments, cDNA fragments which correspond to differentially expressed mRNA species are isolated, reamplified and sequenced according to standard procedures. For instance, bands corresponding the cDNA fragments can be cut from the electrophoresis gel, reamplified and subcloned  
30 into any available vector, including pCRscript using the PCR script cloning kit

(Stratagene). The insert is then sequenced using standard procedures, such as cycle sequencing on an ABI sequencer.

An additional means of analysis comprises hybridization of the amplified fragments to one or more sets of oligonucleotides or nucleic acid fragments  
5 immobilized on a solid substrate. Historically, the solid substrate is a membrane, such as nitrocellulose or nylon. More recently, the substrate is a silicon wafer or a borosilicate slide. The substrate may be porous (Beattie *et al.*, WO 95/11755) or solid. Oligonucleotides are synthesized *in situ* or synthesized prior to deposition on the substrate. Various chemistries are known for attaching oligonucleotide. Many of  
10 these attachment chemistries rely upon functionalizing oligonucleotides to contain a primary amine group. The oligonucleotides are arranged in an array form, such that the position of each oligonucleotide sequence can be determined.

The amplified fragments, which are generally labeled according to one of the methods described herein, are denatured and applied to the oligonucleotides on the  
15 substrate under appropriate salt and temperature conditions. In certain embodiments, the conditions are chosen to favor hybridization of exact complementary matches and disfavor hybridization of mismatches. Unhybridized nucleic acids are washed off and the hybridized molecules detected, generally both for position and quantity. The detection method will depend upon the label used. Radioactive labels, fluorescent  
20 labels and mass spectrometry label are among the suitable labels.

The present invention as set forth in the specific embodiments, includes methods to identify a therapeutic agent that modulates the expression of at least one gene in a T lymphocyte population. Genes which are differentially expressed during T lymphocyte contact with a pathogen, antigen, superantigen, mitogen or allergen, or  
25 that are differentially expressed in a subject having a sterile inflammatory disease, cancer or GVHD are of particular importance.

In general, the method to identify a therapeutic or prophylactic agent that modulates the response of a T lymphocyte population to a pathogen, mitogen, antigen, superantigen or allergen, comprises the steps of preparing a first gene expression  
30 profile of a quiescent T lymphocyte population or subpopulation, preparing a second



gene expression profile of a T lymphocyte population or subpopulation exposed to a pathogen, mitogen, antigen, superantigen or allergen, treating the exposed T lymphocyte population or subpopulation with the agent, preparing a third gene expression profile of the treated T lymphocyte population, comparing the first, second  
5 and third gene expression profiles and identifying agents that modulate the response of a T lymphocyte population or subpopulation to the pathogen, mitogen, antigen, superantigen or allergen.

In another format, the method is used to identify a therapeutic agent that modulates the expression of genes in a T lymphocyte population or subpopulation  
10 found in a human or animal subject having a sterile inflammatory disease, GVHD or cancer. The general method comprises the steps of preparing a first gene expression profile of a T lymphocyte population or subpopulation in a subject having a sterile inflammatory disease GVHD or cancer, treating or exposing the T lymphocyte population or subpopulation to the agent, preparing a second gene expression profile  
15 of the treated T lymphocyte population or subpopulation, comparing the first and second gene expression profiles with the gene expression profile of a normal T lymphocyte population and identifying agents that modulate the expression of genes whose transcription levels are altered in the T lymphocyte population or subpopulation of the subject as compared with normal T lymphocyte population or  
20 subpopulation.

While the above methods for identifying a therapeutic agent comprise the comparison of gene expression profiles from treated and not-treated T lymphocytes, many other variations are immediately envisioned by one of ordinary skill in the art. As an example, as a variation of a method to identify a therapeutic or prophylactic  
25 agent that modulates the response of a T lymphocyte population or subpopulation to pathogen, mitogen, antigen, superantigen or allergen, the second gene expression profile of a T lymphocyte population or subpopulation exposed to a pathogen, antigen, mitogen, immunogen or allergen and the third gene expression profile of the treated T lymphocyte population or subpopulation can each be independently  
30 normalized using the first gene expression profile prepared from a quiescent T

lymphocyte population or subpopulation. Normalization of the profiles can easily be achieved by scanning autoradiographs corresponding to each profile, and subtracting the digitized values corresponding to each band on the autoradiograph from quiescent T lymphocytes from the digitized value for each corresponding band on

- 5 autoradiographs corresponding to the second and third gene expression profiles. After normalization, the second and third gene expression profiled can be compared directly to detect cDNA fragments which correspond to mRNA species, which are differentially expressed upon exposure of the T lymphocyte population or subpopulation to the agent to be tested.

10 *Nucleic Acid Fragments*

- Nucleic acids of the claimed invention include nucleic acids which specifically hybridize to nucleic acids comprising the sequences identified in the Figures. A nucleic acid which specifically hybridizes to a nucleic acid comprising one of the sequences identified in the Figures remains stably bound to said nucleic acid under
- 15 highly stringent or moderately stringent conditions. Stringent and moderately stringent conditions are those commonly defined and available, such as those defined by Sambrook *et al.*, (1989) or Ausubel *et al.*, (1995). The precise level of stringency is not important, rather, conditions should be selected that provide a clear, detectable signal when specific hybridization has occurred.

- 20 Hybridization is a function of sequence identity (homology), G+C content of the sequence, buffer salt content, sequence length and duplex melt temperature ( $T_m$ ) among other variables. See, Maniatis *et al.*, (*Molecular Cloning, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. 1982*). With similar sequence lengths, the buffer salt concentration and temperature provide useful variables for assessing
- 25 sequence identity (homology) by hybridization techniques. For example, where there is at least 90 percent homology, hybridization is commonly carried out at 68°C in a buffer salt such as 6X SSC diluted from 20X SSC. See Sambrook *et al.*, (1989) The buffer salt utilized for final Southern blot washes can be used at a low concentration, *e.g.*, 0.1X SSC and at a relatively high temperature, *e.g.*, 68°C, and two sequences will

form a hybrid duplex (hybridize). Use of the above hybridization and washing conditions together are defined as conditions of high stringency or highly stringent conditions. Moderately stringent conditions can be utilized for hybridization where two sequences share at least about 80 percent homology. Here, hybridization is  
5 carried out using 6X SSC at a temperature of about 50-55°C. A final wash salt concentration of about 1-3X SSC and at a temperature of about 60-68°C are used. These hybridization and washing conditions define moderately stringent conditions.

In particular, specific hybridization refers to conditions in which a high degree of complementarity exists between a nucleic acid comprising the sequences identified  
10 in at least one of the Figures and another nucleic acid. With specific hybridization, complementarity will generally be at least about 75%, 80%, 85%, preferably about 90-100%, or most preferably about 95-100%.

The nucleic acids of the present invention can be used in a variety of ways in accordance with the present invention. For example, they can be used as nucleic acid  
15 probes to screen other cDNA and genomic DNA libraries so as to select by hybridization other DNA sequences that comprise similar sequences. The nucleic acid probe could be RNA or DNA labeled with radioactive nucleotides or by non-radioactive methods (*i.e.*, biotin). Screening could be done at various stringencies (through manipulation of the hybridization  $T_m$ , usually using a  
20 combination of ionic strength, temperature and/or presence of formamide) to isolate close or distantly related homologs. The nucleic acids may also be used to generate primers to amplify cDNA or genomic DNA using polymerase chain reaction (PCR) techniques. The nucleic acid sequences of the present invention can also be used to identify adjacent sequences in the cDNA or genome, for  
25 example, flanking sequences and regulatory elements.

The nucleic acid sequences of the present invention can also be used diagnostically to detect nucleic acid sequences which specifically hybridize to at least one of the sequences identified in the Figures. For instance, said sequences can be used to detect activated T lymphocytes or T lymphocytes previously exposed to a  
30 specific pathogen, mitogen, antigen, superantigen or allergen. As set forth in the

Examples, said sequences are the partial sequences of cDNA species which correspond to T lymphocyte mRNA and therefore genes, which are differentially expressed during T lymphocyte contact with a specific pathogen, mitogen, antigen, superantigen or allergen. Nucleic acid fragments comprising at least part of these  
5 sequences may be used as diagnostic probes to identify T lymphocyte populations that have been activated or have been in contact with a specific pathogen, mitogen, antigen, superantigen or allergen.

In general, nucleic acid fragments comprising at least one of the sequences or part of one of the sequences identified in the Figures can be used as probes to screen  
10 nucleic acid samples from T lymphocyte populations in hybridization assays. Such assays can be used to detect activated T lymphocytes or T lymphocytes exposed to a specific pathogen, mitogen, antigen, superantigen or allergen. To ensure specificity of a hybridization assay using a probe derived from such sequences, it is preferable to design probes which hybridize only with target nucleic acid under conditions of high  
15 stringency. Only highly complementary nucleic acid hybrids form under conditions of high stringency. Accordingly, the stringency of the assay conditions determines the amount of complementarity which should exist between two nucleic acid strands in order to form a hybrid. Stringency should be chosen to maximize the difference in stability between the probe:target hybrid and potential probe:non-target hybrids.

20 Probes may be designed from the sequences of the Figures through methods known in the art. For instance, the G+C content of the probe and the probe length can affect probe binding to its target sequence. Methods to optimize probe specificity are commonly available in Sambrook *et al.*, (1989), or Ausubel *et al.*, (1995).

The nucleic acid sequences of the present invention can also be used as probes  
25 to monitor the expression of at least one differentially expressed T lymphocyte gene in a method to identify a therapeutic or prophylactic agent that modulates the response of a T lymphocyte population to a specific pathogen, mitogen, antigen, superantigen or allergen. In general, the method to identify a therapeutic or prophylactic agent that modulates the response of a T lymphocyte population to a specific pathogen, mitogen,  
30 antigen, superantigen or allergen comprises the steps of determining the expression

level of at least one RNA species that specifically hybridizes to a probe comprising all or part of at least one of the sequences identified in the Figures in a quiescent T lymphocyte population. The expression level of the RNA species is then determined in a T lymphocyte population exposed to a specific pathogen, mitogen, antigen, superantigen or allergen and also in a T lymphocyte population exposed to a specific pathogen, mitogen, antigen, superantigen or allergen and to the agent to be tested. Agents which modulate the expression level of a RNA species associated with T lymphocyte activation by a specific pathogen, mitogen, antigen, superantigen or allergen are thereby identified by comparing the expression levels of the RNA species.

Hybridization assays to determine the expression level of at least one RNA species are commonly available and include the detection of DNA:RNA and RNA:RNA hybrids. Northern blots of total cellular RNA or polyA purified RNA and hybridization assays wherein at least one or part of one of the sequences of the present invention are immobilized to a solid support are included.

Solid supports can be prepared that comprise immobilized representative groupings of nucleic acids corresponding to the sequences or parts of the sequences identified in the Figures. For instance, representative nucleic acids can be immobilized to any solid support to which nucleic acids can be immobilized, such as positively charged nitrocellulose or nylon membranes (see Sambrook *et al.*, 1989), as well as porous glass wafers such as those disclosed by Beattie (WO 95/11755). Nucleic acids are immobilized to the solid support by well established techniques, including charge interactions, as well as attachment of derivatized nucleic acids to silicon dioxide surfaces such as glass which bears a terminal epoxide moiety. A solid support comprising a representative grouping of nucleic acids can then be used in standard hybridization assays to detect the presence or quantity of one or more specific nucleic acid species in a sample (such as a total cellular mRNA sample or cDNA prepared from said mRNA) which hybridize to the nucleic acids attached to the solid support. Any hybridization methods, reactions, conditions and/or detection

means can be used, such as those disclosed by Sambrook *et al.*, (1989), Ausbel *et al.*, (1987), or Beattie (WO 95/11755).

One of ordinary skill in the art may determine the optimal number of nucleic acid species that must be represented by nucleic acid fragments immobilized on the solid support to effectively differentiate between samples, *e.g.*, T lymphocytes exposed to a specific pathogen, mitogen, antigen, superantigen or allergen. Preferably, at least about 1, 5, 10, 20, 28 or more nucleic acid fragments corresponding to at least one or part of one of the sequences identified in the Figures are affixed to a solid support. The skilled artisan will be able to optimize the number and particular nucleic acids for a given purpose, *i.e.*, screening for modulating agents, identifying activated T lymphocytes, *etc.*

#### *Full Length cDNA Fragments*

The determination of the sequences identified in the Figures as derived from T lymphocyte mRNA species (genes) that are differentially regulated in response to exposure of a T lymphocyte population to a specific pathogen, mitogen, antigen, superantigen or allergen enables the isolation of full length cDNA molecules encoding proteins associated with the T lymphocyte response.

As set forth above, any method may be used to prepare a cDNA library from T lymphocytes. Preferably, the cDNA library is produced from T lymphocytes exposed to a specific pathogen, mitogen, antigen, superantigen or allergen. After exposure, the cDNA library is prepared by extracting the mRNA from isolated T lymphocytes, using known methods, for example, isolation of polyadenylated (poly A+) RNA. Kits for isolating poly A+ RNA are commercially available, for example, PolyA Tract kits are available from Promega Corporation. The mRNA thus extracted may be enriched for mRNAs corresponding to genes differentially expressed by hybrid selection procedures, and the like. In instances of a low recovery of RNA, mRNA can be preamplified by PCR using known methods. The cDNAs corresponding to the mRNAs may be prepared using a reverse transcriptase for first strand synthesis and a DNA polymerase for second strand synthesis. Methods for using reverse transcriptase

and DNA polymerase to make cDNA are well known in the art. Kits for performing these techniques are commercially available, for example, the Superscript II™ kit (Gibco-BRL), the Great Lengths cDNA Synthesis Kit™ (Clontech), the cDNA Synthesis Kit (Stratagene), and the like.

5       The cDNAs may then be ligated to linker DNA sequences containing suitable restriction enzyme recognition sites. Such linker DNAs are commercially available, for example, from Promega Corporation and from New England Biolabs and the particular linker used may be selected to conform to the protocol being used. The cDNAs may be subjected to restriction enzyme digestion, size fractionation, or any  
10 other suitable method, to enrich for full-length cDNAs within the library.

      The resultant cDNA library can be modified to select for rare transcripts or for transcripts corresponding to genes that are differentially expressed upon exposure to a specific pathogen, mitogen, antigen, superantigen or allergen. For instance, when using a sequence corresponding to a mRNA which is up-regulated in response to  
15 exposure of a T lymphocyte population to a specific pathogen, mitogen, antigen, superantigen or allergen, a cDNA library is prepared from exposed T lymphocytes and subtractively hybridized to cDNA or mRNA (polyA+ RNA) from a quiescent T lymphocyte population. Subtractive hybridization methods are available, for instance as taught by Davis *et al.*, (1987) *Cell* 51: 987-1000; Hedrick *et al.*, (1984) *Nature*,  
20 308: 149-153; and Sargent *et al.*, (1983) *Science*, 222: 135-139. Subtractive library methods that utilize PCR amplification may also be used as taught, for example, by Wieland *et al.*, (1990) *Proc. Natl. Acad. Sci. USA*, 87: 2720-2724; Wang *et al.*, (1991) *Proc. Natl. Acad. Sci. USA*, 88: 11505-11509; Cecchini *et al.*, (1993) *Nucleic Acids Res.*, 21: 5742-5747; Lebeau *et al.*, (1991) *Nucleic Acids Res.*, 19: 4778; Duguid *et al.*, (1990) *Nucleic Acids Res.*, 18: 2789-2792. and U.S. Patent 5,525,471  
25

      The resultant cDNA library may also be normalized to obtain cDNAs corresponding to rare or weakly expressed mRNA species. Many procedures are available including hybridization of the cDNA library to genomic DNA as taught by Weissman *et al.*, (1987) *Mol. Biol. Med.*, 4: 133-143. Other available techniques  
30 include utilizing second order hybridization kinetics to select for rarer species as

taught by Ko *et al.*, (1990) *Nuc. Acids. Res.*, 18: 5709; Patanjali *et al.*, (1991) *Proc. Natl. Acad. Sci. USA*, 88: 1943-1947 or Soares *et al.*, (U.S. Patent No. 5,637,685).

The cDNA library is then screened from cDNA clones that specifically hybridize to a nucleic acid comprising at least one or part of one of the sequences  
5 identified in the Figures. Such methods are widely available as set forth above.

After isolation of cDNA clones which specifically hybridize to a nucleic acid comprising at least one or part of one of the sequences identified in the Figures, the inserts into the cDNA molecules can be further characterized by known methods including the sequencing of the cDNA insert. In instances where the 5' end of the  
10 cDNA encompassing the amino terminus of an encoded protein is not contained within a cDNA molecule isolated by the above methods, 5'RACE PCR amplification and other known procedures can be used to retrieve the 5' end of the cDNA. Such methods are known in the art and exemplified by Fang *et al.*, (1997) *Biotechniques*, 23 (1): 52, 54, 56, 58; Chen (1996) *Trends Genet.*, 12 (3): 87-88; Lung *et al.*, (1996)  
15 *Trends Genet.*, 12 (10): 389-91; Bahring *et al.*, (1994) *Biotechniques*, 16 (5): 807-8; and Borson *et al.*, (1992) *PCR Methods Appl.*, 2(2): 144-8.

#### *Related Nucleic Acids*

As used herein, the present invention encompasses nucleic acids wherein sequences flanking or contiguous with at least one of the sequences identified in the  
20 Figures include: sequences remaining in the same open reading frame; sequences which do not include a stop codon; sequences which terminate at a stop codon; sequences which serve as a promoter, operator or other regulatory control sequence; or sequences which are derived from genomic DNA.

#### *Vectors and Host Cells*

25 The present invention comprises recombinant vectors containing and capable of replicating and directing the expression of nucleic acids comprising at least one, or part of one of the sequences identified in the Figures in a compatible host cell. The insertion of a DNA in accordance with the present invention into a vector may be



performed by any conventional means. Such an insertion is easily accomplished when both the DNA and the desired vector have been cut with the same restriction enzyme or enzymes, since complementary DNA termini are thereby produced. If this cannot be accomplished, it may be necessary to modify the cut ends that are produced by  
5 digesting back single-stranded DNA to produce blunt ends, or by achieving the same result by filling in the single-stranded termini with an appropriate DNA polymerase. In this way, blunt-end ligation with an enzyme such as T4 DNA ligase may be carried out. Alternatively, any site desired may be produced by ligating nucleotide sequences (linkers) onto the DNA termini. Such linkers may comprise specific oligonucleotide  
10 sequences that encode restriction site recognition sequences.

Any available vectors and the appropriate compatible host cells may be used such as those disclosed by Sambrook *et al.*, (1989) and Ausubel *et al.*, (1995). Commercially available vectors, for instance, those available from New England  
15 Biolabs Inc., Promega Corp., Stratagene Inc. or other commercial sources are included.

### Specific Embodiments

#### Example 1

*Production of gene expression profiles generated from cDNAs made with RNA isolated from quiescent T lymphocytes (Jurkat lymphocytes) and activated T lymphocytes.*

Expression profiles of RNA expression levels from Jurkat lymphocytes exposed to activating agents, such as 12-O-tetradecanoylphorbol-13-acetate (TPA) and phytohemagglutinin (PHA), offer a powerful means of identifying genes that are specifically regulated during T lymphocyte activation.

#### 10 Culturing of Jurkat lymphocytes and Treatment with an Activating Agent

Jurkat lymphocytes (Jurkat clone E6-1; ATCC Accession No. TIB 152) were grown in 6 X 100 ml RPMI culture media supplemented with 10% fetal bovine serum (FBS), penicillin, streptomycin and glutamine. The Jurkat lymphocytes were pelleted in 450 ml RPMI media supplemented with penicillin, streptomycin and glutamine only and were incubated for approximately 24 hours. After 24 hours, FBS was added to a final concentration of 10%. The flasks of Jurkat lymphocytes were incubated for 1 hour. Cells were then pelleted, resuspended in 100 ml PBS, pelleted again and resuspended ultimately in 500 ml RPMI supplemented with 10% FBS, glutamine, streptomycin and penicillin. A small aliquot of the cells was removed, stained with trypan blue and counted. The concentration of cells was determined to be  $2.45 \times 10^6$  (or  $1.225 \times 10^9$  total cells). From the 500 ml suspension, 250 ml was removed to another flask and 250 ml fresh 10% FBS RPMI was added to both flasks making equal aliquots of 500 ml containing  $\sim 1.0 \times 10^6$  cells each. For the non-stimulated (resting or quiescent) Jurkat lymphocytes, five 100 ml flasks were made from one of the 500 ml flasks. The remaining 500 ml flask of Jurkat lymphocytes was treated (stimulated) with 500  $\mu$ l of 2.0 mg/ml phytohemagglutinin (PHA) and 25  $\mu$ l of 1.0 mg/ml tetraphorbol acetate (TPA), which was dissolved in ethanol. Jurkat lymphocytes could also be stimulated using ionomycin (Sigma) and TPA (or phorbol

derivatives). The 500 ml of stimulated cells were then aliquoted into five 100 ml tissue culture flasks. Cells were harvested 4 hours after the addition of PHA and TPA. The cells were pelleted at 1.5xg for at least 5 minutes and the supernatant was removed by pouring. Pellets were then placed on ice for the RNA to be extracted.

## 5 cDNA Preparation

Total cellular RNA was prepared from the untreated and treated Jurkat lymphocytes using the procedure of Newburger *et al.*, (1981) *J. Biol. Chem.* 266(24): 16171-7 and Newburger *et al.*, (1988) *Proc. Natl. Acad. Sci. USA* 85: 5215-5219. Ten micrograms of total RNA, the amount obtainable from about  $3 \times 10^6$  Jurkat

10 lymphocytes, is sufficient for a complete set of cDNA expression profiles.

Synthesis of cDNA was performed as previously described by Prashar *et al.*, in WO 97/05286 and in Prashar *et al.*, (1996) *Proc. Natl. Acad. Sci. USA* 93: 659-663.

Briefly, cDNA was synthesized according to the protocol described in the GIBCO/BRL kit for cDNA synthesis. The reaction mixture for first-strand synthesis

15 included 6  $\mu$ g of total RNA, and 200 ng of a mixture of 1-base anchored oligo(dT) primers with all three possible anchored bases as shown in the table for Figure 1:

(ACGTAATACGACTCACTATAGGGCGAATTGGGTCGACTTTTTTTTTTTTTTTT

TTTn1 wherein n1=A/C or G) (SEQ ID NO.38) along with other components for

first-strand synthesis reaction, except reverse transcriptase. This mixture was

20 incubated at 65°C for 5 min, chilled on ice and the process repeated. Alternatively, the reaction mixture may include 10  $\mu$ g of total RNA, and 2 pmol of one of the 2-base anchored oligo(dT) primers as a heel such as RP5.0

(CTCTCAAGGATCTTACCGCTT<sub>18</sub>AT) (SEQ ID NO.39), or

RP6.0 (TAATACCGCGCCACATAGCAT<sub>18</sub>CG) (SEQ ID NO.40), or RP9.2

25 (CAGGGTAGACGACGCTACGCT<sub>18</sub>GA) (SEQ ID NO. 41) along with other

components for first-strand synthesis reaction except reverse transcriptase. This

mixture was then layered with mineral oil and incubated at 65°C for 7 min followed

by 50°C for another 7 min. At this stage, 2  $\mu$ l of Superscript reverse transcriptase

(200 units/ $\mu$ l; GIBCO/BRL) was added quickly and mixed, and the reaction continued

for 1 hr at 45-50°C. Second-strand synthesis was performed at 16°C for 2 hr. At the end of the reaction, the cDNAs were precipitated with ethanol and the yield of cDNA was calculated.

The adapter oligonucleotide sequences were

- 5 A1 (TAGCGTCCGGCGCAGCGACGGCCAG) (SEQ ID NO.42) and  
A2 (GATCCTGGCCGTCGGCTGTCTGTCGGCGC) (SEQ ID NO.43). One  
microgram of oligonucleotide A2 was first phosphorylated at the 5' end using T4  
polynucleotide kinase (PNK). After phosphorylation, the oligonucleotide was heat  
denatured, and 1 µg of the oligonucleotide A1 was added along with 10× annealing  
10 buffer (1 M NaCl; 100 mM Tris-HCl, pH 8.0; 10 mM EDTA, pH 8.0) in a final vol of  
20 µl. This mixture was then heated at 65°C for 10 min followed by slow cooling to  
room temperature for 30 min, resulting in formation of the Y adapter at a final  
concentration of 100 ng/µl. About 20 ng of the cDNA was digested with 4 units of  
*Bgl* II or another restriction enzyme in a final vol of 10 µl for 30 min at 37°C. Two µl  
15 (≈4 ng of digested cDNA) of this reaction mixture was then used for ligation to 100  
ng (≈50-fold) of the Y-shaped adapter in a final vol of 5 µl for 16 hr at 15°C. After  
ligation, the reaction mixture was diluted with water to a final vol of 80 µl (adapter  
ligated cDNA concentration, 50 pg/µl), heated at 65°C for 10 min to denature T4  
DNA ligase, and 2 µl aliquots (with 100 pg of cDNA) were used for PCR.

- 20 The following sets of primers were used for PCR amplification of the adapter  
ligated 3'-end cDNAs:

- TGAAGCCGAGACGTCGGTCG(T)<sub>18</sub> n1, n2 (wherein n1, n2 = AA, AC, AG  
AT CA CC CG CT GA GC GG or GT) (SEQ ID NO. 44) as the 3' primer with A1 as  
the 5' primer or alternatively, opposing primers used as 3' primers with primer A1.1  
25 serving as the 5' primer. To detect the PCR products on the display gel, 24 pmol of  
oligonucleotide A1 or A1.1 was 5' -end-labeled using 15 µl of [ $\gamma$ -<sup>32</sup>P]-ATP  
(Amersham; 3,000 Ci/mmol) and PNK in a final volume of 20 µl for 30 min at 37°C.  
After heat denaturing at 65°C for 20 min, the labeled oligonucleotide was diluted to a  
final concentration of 2 µM in 80 µl with unlabeled oligonucleotide A1.1. The PCR  
30 mixture (20 µl) consisted of 2 µl (100 pg) of the template, 2 µl of 10× PCR buffer

(100 mM Tris-HCl, pH 8.3; 500 mM KCl), 2  $\mu$ l of 15 mM  $MgCl_2$  to yield 1.5 mM final  $Mg^{2+}$  concentration optimum in the reaction mixture, 200  $\mu$ M dNTPs, 200 nM each 5' and 3' PCR primers (RP primers), and 1 unit of Amplitaq Gold. Primers and dNTPs were added after preheating the reaction mixture containing the rest of the components at 85°C. This "hot start" PCR was done to avoid amplification of artifacts arising out of arbitrary annealing of PCR primers at lower temperature during transition from room temperature to 94°C in the first PCR cycle. PCR consisted of 5 cycles of 94°C for 30 sec; 55°C for 2 min, and 72°C for 60 sec, followed by 25 cycles of 94°C for 30 sec, 60°C for 2 min, and 72°C for 60 sec. A higher number of cycles resulted in smeary gel patterns. PCR products (2.5  $\mu$ l) were analyzed on 6% polyacrylamide sequencing gel. For double or multiple digestion following adapter ligation, 13.2  $\mu$ l of the ligated cDNA sample was digested with a secondary restriction enzyme(s) in a final vol of 20  $\mu$ l. From this solution, 3  $\mu$ l was used as template for PCR. This template volume of 3  $\mu$ l carried 100 pg of the cDNA and 10 mM  $MgCl_2$  (from the 10 $\times$  enzyme buffer), which diluted to the optimum of 1.5 mM in the final PCR volume of 20  $\mu$ l. Since  $Mg^{2+}$  comes from the restriction enzyme buffer, it was not included in the reaction mixture when amplifying secondarily cut cDNA.

Production of gene expression profiles generated using all 12 possible anchoring oligo d(T) n1, n2.

Using the above described methods, RNA was extracted and the cDNA profiles prepared using all 12 possible anchoring oligo d(T)n1, n2.

Figure 1A is an autoradiogram of the expression profiles generated from cDNAs made with RNA isolated from control (untreated) Jurkat lymphocytes and Jurkat lymphocytes incubated with TPA and PHA.

Figure 1B the expression profiles generated from cDNAs made with RNA isolated from control (untreated) Jurkat lymphocytes and activated (treated) Jurkat lymphocytes is an autoradiogram of activated and quiescent Jurkat lymphocytes using the RP 8.6 primers.

-36-

Such autoradiography gels may be scanned using commonly available equipment, such as a UMAX D-1L scanner. Bands which exhibit altered intensities in gene expression profiles from quiescent Jurkat lymphocytes as compared to the gene expression profile prepared from activated (treated) Jurkat lymphocytes can then be extracted from the display gel as previously described above. The isolated fragments can then be reamplified using 5' and 3' primers, subcloned into pCR-Script (Stratagene) and sequenced using an ABI automated sequencer. Alternatively, bands can be extracted (cored) from the display gels, PCR amplified and sequenced directly without subcloning.

10

### Example 2

#### ***Production of gene expression profiles generated from cDNAs made with RNA isolated from T lymphocytes exposed to Staphylococci or Streptococci.***

Expression profiles from T lymphocytes (Jurkat lymphocytes) exposed to virulent and avirulent *Staphylococcus aureus* and *Streptococcus* would allow the identification of T lymphocyte genes that are specifically regulated in response to bacterial infection by these organisms, as well as in response to the superantigens, the bacterial enterotoxins, they contain.

T lymphocytes are cultured as described above in Example 1. The cells are then exposed to either *Staphylococci* or *Streptococci* or the enterotoxins therefrom. When exposing the T lymphocytes to an enterotoxin, the T cells can be directly exposed by the addition of enterotoxin to the culture medium or by addition of bacterial cells to the culture medium. Before incubation, bacteria are harvested and washed in phosphate buffered saline. T lymphocytes are then incubated with the bacteria at a ratio which induces activation of the T lymphocytes. For instance, a T lymphocyte:bacteria ratio of 1:20 would be appropriate in RPMI 1640 (HEPES buffered) in the presence of heat inactivated FBS at 37°C with gentle mixing in a rotary shaker bath.

In instances where an antigen specific response is required, bacterial antigens may be presented to the T lymphocytes in the context of class I or class II major

histocompatibility antigens (MHC). Many methods to present antigen in the context of MHC are readily available, including the exogenous loading of bacterial antigens onto antigen presenting cells, including macrophages and dendritic cells. Such methods include treating an antigen-presenting cell to enhance expression by the cell of empty major histocompatibility complex molecules, followed by reacting the treated antigen presenting cell with an antigen extracorporeally in the presence of a photoactivatable agent and irradiation to form an antigen-associated antigen presenting cell. (See, e.g., PCT application number US93/11220, publication number WO 94/11016). Other available methods include the production of antigen fusions to such molecules as the *Bordetella pertussis* adenylate cyclase (see U.S. Patent 5,679,784), lysosomal/endosomal targeting sequences (see U.S. Patent 5,633,234), the production of empty class II heterodimers comprising antigenic peptides (see U.S. Patent 5,583,031), or the use of exogenously loaded immortalized dendritic cells (see U.S. Patent 5,648,219).

After non-specific activation by exotoxin or antigen specific activation by a Staphylococcal or Streptococcal antigen, expression profiles from the activated cells as well as a quiescent T lymphocyte control population may be made by any means available in the art. Preferably, gene expression profiles are generated as described in Example 1. After autoradiography or another means of detection, cDNA bands corresponding to mRNA species which are differentially expressed are visualized and the band(s) isolated or excised for further analysis as in Example 1.

### **Example 3**

#### ***Production of gene expression profiles generated from cDNAs made with RNA isolated from human T lymphocytes exposed to ionomycin and sn-1,2-dioctanoylglycerol.***

Human T lymphocytes were isolated using the method of Subramaniam *et al.*, (1988) *Cell. Immunol.* 116: 439-449. The cells were treated with ionomycin and sn-1,2-dioctanoylglycerol (diC8) in the same media conditions as described in Example

1. The concentrations of ionomycin and diC8 used to activate the human T lymphocytes were as described in Subramaniam *et al.*

After incubation, RNA was extracted from the treated and untreated human T lymphocytes, and gene expression profiles prepared as described in Example 1.

5 Figure 2A is an autoradiogram of the expression profiles generated from cDNAs made with RNA isolated from control (untreated) Jurkat lymphocytes and human T lymphocytes incubated with ionomycin and diC8.

As exhibited by Figures 2A-2B, the expression of mRNA species in human T lymphocytes exposed to ionomycin and diC8 (as indicated by their corresponding  
10 cDNA fragments) is modulated compared to the expression of mRNA species of unexposed (quiescent) human T lymphocytes. cDNA bands corresponding to mRNA species which are differentially expressed upon exposure to ionomycin and diC8 are identified by comparing the gene expression profile for the treated T lymphocytes to the gene expression profile from the untreated control T lymphocytes and the band(s)  
15 isolated or excised for further analysis as in Example 1.

#### Example 4

##### ***Production of gene expression profiles generated from cDNAs made with RNA isolated from activated human T lymphocytes exposed to cyclosporin.***

The ability to compare gene expression profiles from activated T lymphocytes  
20 to gene expression profiles prepared from activated T lymphocytes treated or exposed to cyclosporin or another immunoinhibitory agent allows the identification and isolation of mRNA species, and therefore genes, that are differentially expressed upon the deactivation of a T lymphocyte population.

Human peripheral blood quiescent T lymphocytes are acquired according to  
25 the procedures set forth in Sehajpal *et al.*, *Cell. Immunol.* 120: 195-204 (1989) and Subramaniam *et al.*, (1988). An aliquot of the T lymphocyte population is activated using diC8 and ionomycin, as described in Example 3. A second aliquot of the T lymphocyte population is treated with diC8, ionomycin and cyclosporin A (CsA). Gene expression profiles are then prepared from the diC8 and ionomycin treated cells,



the diC8, ionomycin and cyclosporin A treated cells and a control untreated quiescent T lymphocyte population according to the methods set forth in Example 1. The resulting gene expression profiles are then compared to identify cDNA bands corresponding the mRNA species that are differentially regulated upon exposure to cyclosporin. For instance, cDNA species corresponding to mRNA species that are either up-regulated or down-regulated in an activated T lymphocyte population upon exposure to cyclosporin are isolated or excised for further analysis, as in Example 1.

### **Example 5**

#### ***Method to identify a therapeutic or prophylactic agent that modulates the response of a proliferating T lymphocyte population.***

The methods set forth in Examples 1 and 3 offer a powerful approach for identifying therapeutic or prophylactic agents that modulate the activity of T lymphocytes or specific T lymphocyte subpopulations (*e.g.*, T<sub>H1</sub> or T<sub>H2</sub>) to either antigen-specific or antigen-nonspecific activation. For instance, an aliquot of a T lymphocyte population that has been activated via an antigen specific or antigen-nonspecific pathway is exposed to the agent to be tested. Gene expression profiles are then prepared as set forth in Example 1. A gene expression profile is also prepared from a control aliquot of the activated T lymphocyte population that has not been exposed to the agent to be tested as well as a quiescent T lymphocyte population. By examining for differences in the intensity of individual bands between the three gene expression profiles, agents which up or down regulate the expression of one or more mRNA species in activated T lymphocytes are identified.

As a specific example, screening for agents which down regulate the expression of at least one gene associated with T lymphocyte activation, such as the human serine esterase gene, provides a means for identifying agents which may be useful as immunoinhibitory drugs. As set forth in the Table of Figure 4, a cDNA band corresponding to the human serine esterase mRNA is among a number of cDNA bands that are up-regulated upon T lymphocyte activation. To screen for such agents, an aliquot of a T lymphocyte population that has been activated via an antigen specific

or antigen-nonspecific pathway is exposed to the agent to be tested. Gene expression profiles are then prepared as set forth in Example 1. Gene expression profiles are also prepared from a control aliquot of the activated T lymphocyte population that has not been exposed to the agent to be tested as well as a quiescent T lymphocyte population. By examining for differences in the intensity of individual cDNA bands identified as being up-regulated in the TableS of Figures 4 or 5, such as the cDNA band corresponding the mRNA encoding human serine esterase, agents which down regulate the expression of one or more mRNA species in activated T lymphocytes are identified. Agents that down regulate expression of human serine esterase, as demonstrated by decreased band density in the profile produced from activated T lymphocytes exposed to the agent, may be useful in modulating the activation of a T lymphocyte population.

#### **Example 6**

***Method to identify a therapeutic or prophylactic agent that modulates the response of a T lymphocyte population to a pathogen.***

The methods set forth in Examples 1 and 3 also offer a powerful approach for identifying therapeutic or prophylactic agents that modulate the activation of T lymphocytes or specific T lymphocyte subpopulations (e.g.,  $T_{H1}$  or  $T_{H2}$ ) to a pathogen (e.g., a virus, bacteria or fungi) or parasite. An aliquot of an isolated T lymphocyte population or subpopulation is exposed to a pathogen or parasite of interest such as *Staphylococcus aureus*, a *Streptococcus* species or *Mycobacterium leprae*. Exposure of the T lymphocyte population to the pathogen or parasite antigens can be facilitated by the presentation of pathogen or parasite antigens to the T lymphocyte population in the context of class I or class II MHC using commonly available methods, such as those disclosed in Example 2. A second aliquot of the same T lymphocyte population is then exposed to the pathogen or parasite antigens as above in the presence of the agent to be tested. Gene expression profiles are then prepared from the two aliquots, as well as from a quiescent T lymphocyte population, by the methods set forth in Example 1. By examining for differences in the intensity of

individual bands between the three profiles, agents which up- or down-regulate genes of interest in the pathogen or parasite exposed T lymphocytes can be identified. Such agents can be used, for example, as immunostimulatory agents to up-regulate antigen specific T lymphocyte activation.

5

#### Example 7

*Method to identify a therapeutic or prophylactic agent that modulates the activity of a T lymphocyte population found in a subject having a sterile inflammatory disease, immunodeficiency disorder, autoimmune disorder or T lymphocyte neoplasm.*

The methods set forth in Examples 1 and 3 also offer a powerful approach for  
10 identifying therapeutic or prophylactic agents that modulate the expression of T lymphocytes or T lymphocyte subpopulations in subjects exhibiting the symptoms of a sterile (non-infectious) inflammatory disease, immunodeficiency disorder, autoimmune disorder or T lymphocyte neoplasm (hereinafter in this example to be referred to as "T lymphocyte disease"). T lymphocytes from a subject exhibiting the  
15 symptoms of a T lymphocyte disease are isolated according to readily available methods, for instance, the methods disclosed in Subramaniam *et al.*, (1988) *Cell. Immunol.* 116: 439-449.

To test agents for their effects on T gene expression, an aliquot of the T lymphocyte population isolated from the subject is then treated or exposed to the  
20 agent to be tested. Gene expression profiles are then prepared from the aliquot of the T cell population exposed to the agent, from an aliquot of the same T lymphocyte population isolated from the subject and from a quiescent T lymphocyte population isolated from a normal subject not exhibiting the symptoms of a T lymphocyte disease the according to the methods set forth in Example 1. By examining these profiles for  
25 differences in the intensity of bands between the three profiles, agents which up- or down-regulate genes of interest in a T lymphocyte population from a subject exhibiting the symptoms of a T lymphocyte disease can be identified. Agents that up-regulate a gene or genes that are expressed at abnormally low levels in a T lymphocyte population from a subject exhibiting the symptoms of a T lymphocyte

disease compared to a normal T lymphocyte population, as well as agents that down-regulate a gene or genes that are expressed at abnormally high levels in a T lymphocyte population from a subject exhibiting the symptoms of a T lymphocyte disease are identified.

5

**Example 8*****Method of isolating agents that modulate virus infected T lymphocytes.***

The methods set forth in Examples 1 and 3 are also useful for identifying therapeutic or prophylactic agents that modulate the response of T lymphocytes or T lymphocyte subpopulations to viral infection. Many viruses demonstrate a tropism  
10 for T lymphocyte populations, including but not limited to HIV and HTLV I.

T lymphocyte populations infected with a given virus are isolated from a subject exhibiting symptoms of viral infection. Alternatively, normal uninfected T lymphocyte cell lines or uninfected T lymphocytes are isolated from an uninfected subject and infected with the virus of interest *in vitro*. An aliquot of the T lymphocyte  
15 population infected with the virus is then exposed to the agent to be tested.

Expression profiles are then prepared from the treated T virus infected T lymphocyte aliquot, an aliquot of the virally infected T lymphocyte population which has not been exposed to the agent, and a control population of normal quiescent T lymphocytes using the methods described in Examples 1 and 3. The profiles are then compared to  
20 identify agents that beneficially modulate the T lymphocyte response to viral infection. For instance, agents are identified that modulate the expression level of at least one gene whose expression level is down-regulated upon viral infection.

Alternatively, agents are identified that modulate the expression level of at least one gene whose expression level is up-regulated in response to viral infection.

**Example 9*****Method of isolating agents that induce differentiation of pre-T lymphocytes and cortical or medullary thymocytes.***

The methods set forth in Examples 1 and 3 may be used to identify therapeutic  
5 or prophylactic agents that induce differentiation of pre-T lymphocytes and cortical or  
medullary thymocytes. Pre-T lymphocytes or thymocytes are obtained using flow  
cytometry and antibodies for specific markers that are expressed on these cells. Once  
the pre-T lymphocytes or thymocytes are isolated, an aliquot of the cells are treated or  
exposed to the agent to be tested. An expression profile is then prepared from this  
10 exposed cell population, an aliquot of the same cell population which has not been  
exposed to the agent and a population of differentiated T lymphocytes. This  
population may be selected from the group consisting of cells of the following  
lineages:  $T_{H2}$ ,  $T_{DTH}$ ,  $T_{CTL}$ ,  $T_{H2}$ ,  $T_S$ , memory T lymphocytes, effector T lymphocytes,  
pre-T lymphocytes, cortical T lymphocytes, medullary T lymphocytes, and peripheral  
15 T lymphocytes. The profiles generated from the exposed T lymphocyte population  
and the control cells are then compared to the expression profiles of the specific  
differentiated T lymphocyte subpopulations (either activated or resting T lymphocyte  
subpopulations) to identify agents that dedicate the pre-T lymphocyte or thymocyte to  
a particular T lymphocyte subpopulation (e.g.,  $T_{H2}$ ,  $T_{DTH}$ ,  $T_{CTL}$ ,  $T_{H2}$ ,  $T_S$ , memory T  
20 lymphocytes, effector T lymphocytes, pre-T lymphocytes, cortical T lymphocytes,  
medullary T lymphocytes, and peripheral T lymphocytes).

**Example 10**

***Production of articles to which are attached or adsorbed selected groupings of  
nucleic acids that correspond to the genes whose expression levels are modulated in  
25 a T lymphocyte population that has been exposed to a pathogen, mitogen,  
immunogen, allergen, antigen, or superantigen.***

As set forth in Examples 1 and 3, expression profiles from T lymphocytes, for  
example, that have been exposed to a pathogen, mitogen, immunogen, allergen,

antigen or superantigen yield the identity of genes whose expression levels are modulated compared to unexposed T lymphocyte populations.

Suitable solid supports can be prepared by those skilled in the art that comprise immobilized representative groupings of nucleic acids corresponding to the genes or fragments of the genes from T lymphocytes whose expression levels are modulated in response to exposure to a pathogen, mitogen, immunogen, superantigen or antigen. For instance, representative nucleic acids can be immobilized to any solid support to which nucleic acids can be immobilized, such as positively charged nitrocellulose or nylon membranes (see SAMBROOK *ET AL.*, (1989) as well as porous glass wafers, such as those disclosed by Beattie (WO 95/11755). Nucleic acids are immobilized to the solid support by well established techniques, including charge interactions, as well as attachment of derivatized nucleic acids to silicon dioxide surfaces such as glass which bears a terminal epoxide moiety. A solid support comprising a representative grouping of nucleic acids can then be used in standard hybridization assays to detect the presence or quantity of one or more specific nucleic acid species in a sample (such as a total cellular mRNA sample or cDNA prepared from said mRNA), which hybridize to the nucleic acids attached to the solid support. Any hybridization methods, reactions, conditions and/or detection means can be used, such as those disclosed by SAMBROOK *ET AL.*, (1989), AUSBEL *ET AL.*, (1987), or Beattie (WO 95/11755).

One of ordinary skill in the art may determine the optimal number of genes and species of genes should be represented by nucleic acid fragments immobilized on the solid support to effectively differentiate between the gene expression profiles of, e.g., T lymphocytes exposed to various pathogens and T cells not exposed to the pathogens. Preferably, at least about 1, 5, 10, 20, 50, 100, 150, 200, 300, 500, 1000, 10,000, or more preferably, substantially all of the detectable mRNA species in a cell sample or population will be present in the gene expression profile or array affixed to a solid support. More preferably, such profiles or arrays will contain a sufficient representative number of mRNA species whose expression levels are modulated under the relevant infection or other exposure. In most instances, a sufficient representative

number of such mRNA species will be at least about 1, 2, 5, 10, 15, 20, 25, 30, 40, 50, 50-75 or 100 in number and will be represented by the nucleic acid molecules or fragments of nucleic acid molecules immobilized on the solid support. The skilled artisan will be able to optimize the number and particular nucleic acids for a given  
5 purpose, *i.e.*, screening for modulating agents, identifying activated T lymphocytes and activated T lymphocyte subpopulations, *etc.*

#### **Example 11**

***Production of solid support articles comprising groupings of nucleic acids that correspond to the genes whose expression levels are modulated in a T lymphocyte  
10 population from a subject having a sterile inflammatory disease, autoimmune disorder, immunodeficiency disorder or T lymphocyte neoplasm.***

The method, compositions and solid support articles set forth in Example 10 can also be used to prepare a solid support that presents nucleic acids that correspond to genes whose expression levels are modulated in T lymphocytes from a subject  
15 having a T lymphocyte disease compared to normal, quiescent T lymphocytes, to prothymocytes, or to various subpopulations of T lymphocytes. Solid supports may also be prepared that comprise immobilized representative groupings of nucleic acids corresponding to the genes or fragments of said genes from T lymphocytes whose expression levels are modulated in the subject.

20

#### **Example 12**

***Method of diagnosing exposure of a subject to a pathogen.***

Expression profiles of RNA expression levels from T lymphocytes exposed to various pathogens or pathogen antigens offer a powerful means to diagnose exposure  
25 of a subject to a pathogen. As set forth in Examples 1 and 3, the display patterns generated from cDNAs made with RNA isolated from T lymphocytes exposed to pathogenic *S. aureus* or *Streptococcus* may exhibit unique patterns of cDNA species corresponding to T lymphocyte mRNA species (genes) whose expression levels are modulated in response to contact of the T lymphocytes with the bacteria or with the

bacterial enterotoxin. The contacting of T lymphocytes with different species of pathogens or pathogen antigen may result in the production of expression profiles that are unique to each pathogen species or strain. These unique expression profiles are useful in diagnosing whether a subject has been exposed to or is infected with a given  
5 pathogen.

Briefly, expression profiles are produced as set forth in Example 1 and 3, using T lymphocyte samples exposed to various pathogens, such as pathogenic strains of *Staphylococci* or *Streptococci*. T lymphocytes are then isolated from the subject to be tested for exposure to a pathogen and an expression profile prepared from the  
10 subject's T lymphocytes by the methods set forth above. The expression profile prepared from the subject T lymphocytes can then be compared to the expression profiles prepared from T lymphocytes exposed to, for example pathogenic *Staphylococci* or *Streptococci*, and also compared to expression profiles of cells exposed to non-pathogenic strains or quiescent lymphocytes. From such a  
15 comparison, it can be determined which expression profile most closely matches the expression profile prepared from the subject, thereby, diagnosing exposure of the subject to a pathogen.

### Example 13

*Method of diagnosing a sterile inflammatory disease, autoimmune disorders, or  
20 immunodeficiency disorders in a subject.*

Expression profiles of RNA expression levels from T lymphocytes isolated from a subject having a sterile inflammatory disease, autoimmune or immunodeficiency disorder offer a powerful means to diagnose inflammatory diseases (e.g., psoriasis, rheumatoid arthritis, glomerulonephritis, asthma, allergic rhinitis,  
25 cardiac and renal reperfusion injury, thrombosis, adult respiratory distress syndrome, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, periodontal disease, etc.). As set forth in Examples 1 and 3, the gene expression profiles generated from cDNAs made with RNA isolated from T lymphocytes from subjects having various sterile inflammatory diseases, autoimmune disorders or



immunodeficiency disorders may exhibit unique patterns of cDNA species corresponding to T lymphocyte mRNA species (genes), whose expression levels are modulated during the inflammatory process. These unique expression profiles are useful in diagnosing whether a subject has a sterile inflammatory disease.

5 Briefly, expression profiles are produced as previously set forth, using T lymphocyte samples isolated from patients with various sterile inflammatory diseases. T lymphocytes are then isolated from the patient to be tested (*e.g.*, diagnosed) and an expression profile prepared from the patient's T lymphocytes by the methods previously set forth. The expression profile prepared from the subject T lymphocytes  
10 can then be compared to the expression profiles prepared from T lymphocytes isolated from patients with various sterile inflammatory diseases, immunodeficiency disorders, or autoimmune disorders to determine which expression profile most closely matches the expression profile prepared from the patient, thereby, diagnosing whether the patient has a sterile inflammatory disease, immunodeficiency disorder or autoimmune  
15 disorder.

#### **Example 14**

##### ***Method of diagnosing graft versus host disease (GVHD) in a subject.***

Expression profiles of mRNA expression levels from T lymphocytes isolated from a subject suffering from or possibly suffering from graft versus host disease  
20 (GVHD) offer a powerful means of diagnosing GVHD prior to the expression of severe symptoms. The early detection of GVHD could aid in decreasing the morbidity associated with allografts and xenografts.

Briefly, expression profiles are obtained from an individual who received an autologous graft or less preferably, from a normal person. An expression profile of T  
25 lymphocytes obtained from individuals at various stages in the course of GVHD would also be obtained. The two expression profiles would then be compared to the expression profile obtained from a patient who recently received an allograft or xenograft. From such a comparison, it can be determined whether the patient is

rejecting his or her grafted tissue. Such early detection of GVHD may save the life of the transplant recipient.

It should be understood that the foregoing discussion and examples merely present a detailed description of certain preferred embodiments. It therefore should be  
5 apparent to those of ordinary skill in the art that various modifications and equivalents can be made without departing from the spirit and scope of the invention. All references, articles and patents identified above are herein incorporated by reference in their entirety.

**What is Claimed Is:**

1. A method to identify a therapeutic or prophylactic agent that modulates the response of a lymphocyte population to an antigen, comprising the steps of:
    - preparing a first gene expression profile of a quiescent lymphocyte  
5 population;
    - preparing a second gene expression profile of a lymphocyte population exposed to the antigen;
    - treating the exposed lymphocyte population with a candidate compound;
    - preparing a third gene expression profile of the treated lymphocyte  
10 population;
    - comparing the first, second and third gene expression profiles; and
    - identifying as a therapeutic or prophylactic agent a compound that modulates the response of a lymphocyte population to the antigen.
  2. The method of claim 1, wherein the lymphocyte is a T lymphocyte.
  - 15 3. The method of claim 1, wherein the lymphocyte is a B lymphocyte.
  4. The method of claim 2, wherein the T lymphocyte population is selected from the group consisting of a population of  $T_{H1}$ ,  $T_{DTH}$ ,  $T_{CTL}$ ,  $T_{H2}$ ,  $T_S$ , memory T lymphocytes, effector T lymphocytes, pre-T lymphocytes, cortical T lymphocytes, medullary T lymphocytes, peripheral T lymphocytes, activated T lymphocytes,  
20 quiescent T lymphocytes, and neoplastic T lymphocytes.
- The method of claim 3, wherein the pathogen is selected from the group consisting of bacteria, viruses, parasites, mycoplasma, protozoans, and fungi.

5. The method of claim 2, wherein the antigen is selected from the group consisting of a pathogen, an antigen derived from a pathogen, an allergen, a superantigen or self-antigen.

6. The method of claim 5, wherein the pathogen is selected from the group consisting of bacteria, viruses, parasites, mycoplasma, protozoans, and fungi.

7. The method of claim 6, wherein the virus is selected from the group consisting of EBV, HIV-1, HTLV-I, HTLV-II, rabies virus, mouse mammary tumor virus, cytomegalovirus, poliovirus, Group C adenoviruses, herpes simplex virus, cytomegalovirus, rubella, measles, mumps, respiratory syncytial virus, vesicular stomatitis virus, influenza A, parainfluenza, and lymphocytic choriomeningitis virus.

8. The method of claim 2, wherein the T lymphocyte population is exposed to the antigen associated with major histocompatibility molecules.

9. The method of claim 8, wherein the major histocompatibility molecules are exposed on the surface of antigen presenting cells.

10. The method of claim 8, wherein the major histocompatibility molecules are selected from the group consisting of Class I MHC and Class II MHC.

11. The method of claim 9, wherein the antigen presenting cells are selected from the group consisting of B lymphocytes, macrophages and dendritic cells.

12. A method to identify a therapeutic or prophylactic agent that modulates a T lymphocyte population found in a subject having a sterile inflammatory disease, autoimmune disorder, immunodeficiency disease, cancer, or GVHD comprising the steps of:

5       preparing a first gene expression profile of a T lymphocyte population in a subject having the sterile inflammatory disease, autoimmune disorder, immunodeficiency disease, cancer, or GVHD;

          treating the T lymphocyte population with a candidate compound;

          preparing a second gene expression profile of the treated T lymphocyte  
10   population;

          comparing the first and second gene expression profiles with a gene expression profile of a normal T lymphocyte population; and

          identifying as a therapeutic or prophylactic agent a compound that modulates a T lymphocyte population found in a subject having a sterile inflammatory  
15   disease, autoimmune disorder, immunodeficiency disease, cancer, or GVHD.

13. The method of claim 12, wherein the T lymphocyte population is selected from the group consisting of a population of  $T_{H1}$ ,  $T_{DTH}$ ,  $T_{CTL}$ ,  $T_{H2}$ ,  $T_S$ , memory T lymphocytes, effector T lymphocytes, pre-T lymphocytes, cortical T lymphocytes, medullary T lymphocytes, and peripheral T lymphocytes.

20       14. The method of claim 12, wherein the sterile inflammatory disease is selected from the group consisting of psoriasis, rheumatoid arthritis, glomerulonephritis, asthma, allergic rhinitis, cardiac and renal reperfusion injury, thrombosis, adult respiratory distress syndrome, inflammatory bowel disease, Crohn's

disease, ulcerative colitis, periodontal disease, lymphocytopenias, autoimmune lymphoproliferative syndrome, synovitis, sarcoidosis, DiGeorge's syndrome, Nezelof syndrome, severe combined immunodeficiency syndromes, Wiskott-Aldrich syndrome, Ataxia-telangiectasia, Cartilage-hair hypoplasia, immunodeficiency with

5 thymoma, and leukocyte adhesion deficiency 1.

15. The method of claim 12, wherein the cancer is selected from the group consisting of: precursor T-lymphoblastic lymphoma/leukemia, T lymphocyte chronic lymphocytic leukemia/prolymphocytic leukemia, T lymphocyte type large granular lymphocyte leukemia, Mycosis fungoides/Sézary syndrome, unspecified peripheral T

10 lymphocyte lymphomas, angioimmunoblastic T lymphocyte lymphoma, nasal type T/NK cell (angiocentric) lymphoma, intestinal T lymphocyte lymphoma with or without associated enteropathy, hepatosplenic  $\gamma\delta$  T lymphocyte lymphoma, subcutaneous panniculitic T lymphocyte lymphoma, adult T lymphocyte lymphoma/leukemia, anaplastic large cell lymphoma, T lymphocyte hairy cell

15 leukemia, and T lymphocyte chronic lymphocytic leukemia.

16. The method of claim 12, wherein the immunodeficiency disease or autoimmune disorder is selected from the group consisting of: rheumatoid arthritis, spondyloarthropathies, systemic lupus erythematosus, HIV-1, polymyositis, inclusion body myositis, SCIDs, Wiskott-Aldrich syndrome, Swiss-type agammaglobulinemia,

20 thymic aplasia, Ataxia Telangiectasia, bare lymphocyte syndrome, immune deficiency with thymoma, transient hypogammaglobulinemia of infancy, DiGeorge's syndrome, Nezelof's syndrome, autosomal recessive lymphopenia with normal or

abnormal immunoglobulins, Omenn's syndrome, and idiopathic CD4+ lymphocytopenia.

17. A article of manufacture comprising a grouping of nucleic acids affixed to a solid support, said nucleic acids corresponding to genes whose expression levels are  
5 modulated in a T lymphocyte population that has been exposed to an antigen.

18. An article of manufacture comprising a grouping of nucleic acids affixed to a solid support, said nucleic acids corresponding to genes whose expression levels are modulated in a T lymphocyte population found in a subject having a sterile inflammatory disease, autoimmune disorder, immunodeficiency disease, cancer, or  
10 GVHD.

19. A method of diagnosing exposure of a subject to an antigen comprising the steps of:

preparing a first gene expression profile of a T lymphocyte population from the subject;

15 comparing the first gene expression profile to a second gene expression profile of a T lymphocyte population exposed to an antigen and to a third gene expression profile of a normal T lymphocyte preparation; and

determining if the subject was exposed to an antigen.

20. The method of claim 19, wherein the antigen is a pathogen, antigen  
20 derived from a pathogen, allergen, superantigen or self-antigen.

21. A method of diagnosing a sterile inflammatory disease, autoimmune disorder, immunodeficiency disease, cancer, or GVHD in a subject, comprising the steps of:

preparing a first gene expression profile of a T lymphocyte population  
5 from the subject;

comparing the first gene expression profile to at least one second gene expression profile from a T lymphocyte population from a subject having a sterile inflammatory disease, autoimmune disorder, immunodeficiency disease, cancer, or GVHD and to a third gene expression profile of a normal T lymphocyte population;  
10 and

determining if the subject has a sterile inflammatory disease, autoimmune disorder, immunodeficiency disease, cancer, or GVHD.

22. A method to identify a therapeutic or prophylactic agent that modulates a T lymphocyte population that arises from a genetic defect, comprising the steps of:

15 preparing a first gene expression profile of a T lymphocyte population that arises from the genetic defect;

treating the first T lymphocyte population with the agent;

preparing a second gene expression profile of the treated T lymphocyte population;

20 comparing the first and second gene expression profiles with a gene expression profile of a normal T lymphocyte population; and



-55-

identifying agents that modulate a T lymphocyte population that arises from a genetic defect.

23. The method of claim 22, wherein the T lymphocyte population is selected from the group consisting of a population of  $T_{H1}$  cells,  $T_{H2}$  cells,  $T_{DTH}$  cells,  $T_{CTL}$  cells,  $T_S$  cells, memory T lymphocytes, effector T lymphocytes, pre-T lymphocytes, cortical T lymphocytes, medullary T lymphocytes, peripheral T lymphocytes, neoplastic cells, LAK cells, and TIL cells.

24. The method of claim 22, wherein the genetic disease is selected from the group consisting of: irritated valve disease, Crohn's disease, asthma, lymphocytopenia, autoimmune lymphoproliferative syndrome, rheumatoid arthritis, DiGeorge syndrome, Nezelof syndrome, SCIDs, Wiskott-Aldrich syndrome, Ataxia-telangiectasia, Cartilage-hair hypoplasia, immunodeficiency with thymoma, leukocyte adhesion deficiency 1, graft vs. host disease, non-Hodgkin's lymphoma, Hodgkin's disease, cutaneous T lymphocyte lymphoma, adult T-cell leukemia/lymphoma, anaplastic large cell lymphoma, chronic lymphocytic leukemia, prolymphocytic leukemia, small cell cerebriform (mycosis fungoides, Sezary syndrome), lymphoepithelioid (Lennert's lymphoma), angioimmunoblastic (AILD, LgX), T-zone lymphoma, pleomorphic — small cell (HTLV-I ±).

25. A article of manufacture comprising a grouping of nucleic acids affixed to a solid support, said nucleic acids corresponding to genes whose expression levels are modulated in a T lymphocyte population that contains a genetic defect.

-56-

26. A method to identify an agent that induces the differentiation of quiescent pre-T lymphocytes, cortical T lymphocytes or medullary T lymphocytes into a differentiated T lymphocyte subpopulation, comprising the steps of:

preparing a first gene expression profile of a quiescent pre-T lymphocyte population, cortical T lymphocyte population or medullary T lymphocyte population;

preparing a second gene expression profile of a quiescent pre-T lymphocyte population, cortical T lymphocyte population or medullary T lymphocyte population exposed to a candidate compound;

preparing a third gene expression profile of a differentiated T lymphocyte population;

comparing the first, second and third gene expression profiles; and identifying as an agents a compound that induces differentiation.

27. The method of claim 26, wherein the differentiated T lymphocyte population is selected from the group consisting of a population of  $T_{H1}$  cells,  $T_{H2}$  cells,  $T_{DTH}$  cells,  $T_{CTL}$  cells,  $T_S$  cells, memory T lymphocytes and effector T lymphocytes.

28. An isolated nucleic acid molecule comprising a DNA molecule selected from the group consisting of: (1) the DNA molecules of SEQ ID NOS. 16, 22, 24, 25, 31, 33, and 34; and (2) a nucleic acid that specifically hybridizes to any one of the DNA molecules of SEQ ID NOS. 16, 22, 24, 25, 31, 33, and 34.

29. The isolated nucleic acid fragment of claim 26 which consists of any one of the DNA molecules of SEQ ID NOS. 16, 22, 24, 25, 31, 33, and 34.

-57-

30. The isolated nucleic acid of claim 26, wherein the specifically hybridizing nucleic acid is of the form R-X-R'

wherein X is any one of the DNA molecules of SEQ ID NOS.16, 22, 24, 25, 31, 33, and 34;

5 wherein R and R' are sequences contiguous with X; and


wherein R and R' may or may not be contiguous.

31. A vector comprising the isolated nucleic acid molecule of any one of claims 28 to 30.


32. A transformed host cell comprising the vector of claim 31.




10 33. The isolated nucleic acid molecule of claim 28, comprising the DNA molecule of SEQ ID NO. 34 or a nucleic acid that specifically hybridizes to that DNA molecule.

**FIG. 1A**




**FIG. 1B**



**FIG. 2A****FIG. 2B****FIG. 2C**

\* PARTIAL PATTERNS SHOWN REPRESENT APPROXIMATELY  
5% OF COMPLETE PATTERN (ALL GENES EXPRESSED).

**FIG. 3**

**FIG. 4**

Differential Display Summary of Results					
No.	Clones	NIN2	Expression Patterns		Gene Bank Search and Analysis
			Control T cells	Activated T cells	
1	TA1		0	+	Unknown
2	JkA1		+	+++	Unknown
3	JkA2		+	+++	Unknown
4	JkA3		+/-	++	Unknown
5	JkA4		+/-	++	Unknown
6	JkA5		+	+++	Unknown
7	JkA6		0	+	Unknown
8	JkA7		0	+++	Unknown
9	JkA8		++	+++	Unknown
10	JkA9		++	+++	Unknown
11	JkA10		+/-	+++	Unknown
12	JkA11		++	+++	Human Serine Esterase
13			0	++	
14			0	++	Human Ribosomal Protein 58



*FIG. 4 cont.*

Differential Display Summary of Results				
No.	Clones	N1N2	Expression Patterns	
			Control T cells	Activated T cells
15			0	++
16			0	++
Gene Bank Search and Analysis				
Unknown				
Protein Translation Factor SVJ1				

FIG. 5

Clone v. Name	Enzyme	Band No.	R.P.	Level of Regulation*	Match (if any)	Percent ID	GenBank Accession	SEQ ID NO.
02_SV_011398_S AC7E_02	Bln I	11	10.2	4X I	Human mRNA for actin binding protein p57	98.182	HUMP57B	14
02_SV_011698_B SSIBAND26_02	Bln I	4	8.5	Absent	Human mRNA for KIAA0120 gene	99.194	HUMORFFA	15
04_SV102897_2A	Bln I	12	10.2	2X I	No human match			16
06_SV102897_1B	Bln I	5	8.5	1.5X I	Human ferritin light subunit mRNA	95.918	HUMFERLA	17
06_SV_011398_S AC14A_06	Bln I	13	10.2	2X I	Human STS W1-30177	98.611	G23064	18
08_SV102897_2B	Bln I	6	9.4	2X I				
10_NS108E_10	Bln I	14	10.2	1.5X I	Human DNA sequence from BAC 397C4	94.554	HS397C4	19
10_SV102897_1C	Bln I	7	9.4	Absent	Human clone 23732 mRNA	99.559	HSU79258	20
10_SV_011398_S AC15D_10	Bln I	15	10.2	3X I	Human hsc70 gene for 71 kd heat shock	98.785	HSWSC70	21
12_SV102897_2C	Bln I	18	10.3	2X I	Human colon carcinoma laminin-binding pr	99.602	HUMLAMB	
14_SV102897_1D	Bln I	9	9.4	2X I	No human match			22
16_SV102897_2D	Bln I	10	9.4	(Absent in R	Human mRNA export protein Rael	98.788	HSU84720	23
18_SV102897_1E	Nsi I	8	8.4	2X I	No human match			24
19_SV011698_BS SIBAND15_19	Sac I	1	8.3	2X I	No human match			25

8 / 8

FIG. 5 cont.

Clone v. Name	Enzyme	Band No.	R.P.	Level of Regulation*	Match (if any)	Percent ID	GenBank Accession	SEQ ID NO.
20_SV102897_2E	Sac I	14	8.6	----	Human ferritin L chain mRNA	100	HUMFERL	26
23_SV011698_BS SIBAND17_23	Sac I	15	8.6	1.5X1	Human mRNA for P1cdc47	100	HUMPI CDC47	27
24_SV102897_2F	Sac I	7	8.4	Absent	Human pancreatic tumor-related protein	99.512	HUMPANCAN	28
26_SV102897_1G	BssSI	15	8.6	2X1	Homo sapiens HLA-B gene	100	D83956	29
27_SV_011698_B SSIBAND19_27	BssSI	17	9.2	2X1	Homo sapiens MLN50 mRNA	97.5	HSMLN50	30
30_SV102897_1H	BssSI	19	9.4	2X1	No human match			31
31_SV_011698_B SSIBAND22_31	BssSI	22	10.2	4X1	Human platelet activating factor acetylch	97.826	HSLIS10	32
37_SV_010898_S AC_BAND1_37	BssSI	26	10.3	2.5X1	No human match			33

\* Gene expression in Activated tissue is represented as (1) or down (1) regulated with respect to Resting Jurkat tissue. X represents fold increase or decrease in expression levels.

## SEQUENCE LISTING

<110> Gene Logic, Inc., c/o Dr. Larry Tiffany

<120> Process to Study Changes in Gene Expression in T  
Lymphocytes

<130> gene logic 5004pr expression T lymphs

<140> 60/084,329

<141> 1998-05-05

<160> 44

<170> PatentIn Ver. 2.0

<210> 1

<211> 238

<212> DNA

<213> Jurkat cell cDNA

<400> 1

```

gatcctatgt nccccccagg cggctggcan tccccacggg aagtgtccac tgaggtcct 60
gagatggata cctctacctg acatggcctg aagatgcagg gcagaggaat tgcccatgga 120
cagtgcgcga aggactaggc tgggagggag cgtgccaacc cttttgcct ctgggtttgg 180
ggagcggagg gcctcttctt ggtgccctgc cccaataaa ggaactggac naagagat 238

```

<210> 2

<211> 174

<212> DNA

<213> Jurkat cell cDNA

<400> 2

```

gatctcatga tgtggctgtt gggaagatgg tggggtttgt ttgccagctt ggagtcctat 60
taaatgaaag ccagcaactc atgttggtta taggtctact gtgggaacag ttatccctaa 120
ccacagctca aaatcgctat catctttagn caaattaaaa tctatgtggc agcg 174

```

<210> 3

<211> 175

<212> DNA

<213> Jurkat cell cDNA

<400> 3

```

gatctggtga ctggcttttc gttctgtgtt cttggcttcc taaatttata tgcccatatg 60
attctcatgc atttgatatt tatgtttaaa agtgtttata tatgtatgta aaaagggaac 120
catatgtttt gagaatttgt aaagtgcagg acatgatcct attaaaataa gaagg 175

```

<210> 4

&lt;211&gt; 285

&lt;212&gt; DNA

&lt;213&gt; Jurkat cell cDNA

&lt;400&gt; 4

```

gatcctccat ggcccagcaa ggcccaagat aaatccttna ccacccaggc accctgtgag 60
cccaacaggt taattagtcc attaatTTTA gtgggacctg catatgttga aaattaccaa 120
tactgactga catgtgatgc tgacctatga taagggtgag tatttattag atgggaaggg 180
aaatttgggg attatttata ctcctgggga cagtttgggg aggattattt attgtattta 240
tattgaatta tgtacttttt tcaataaagt cttatttttg tggcg 285

```

&lt;210&gt; 5

&lt;211&gt; 182

&lt;212&gt; DNA

&lt;213&gt; Jurkat cell cDNA

&lt;400&gt; 5

```

gatctgaaac ccagggttagg catgacattt cancccaaaa ccctacctca tctgttctga 60
aagacgctga aactncctgg gatgttttcg ggnacaagaa tgtanatttn ccctatccct 120
gnacttggtt taatcnaatc aatgtgtgta ttagaataaa agtcacagca tcccaaaagc 180
cg 182

```

&lt;210&gt; 6

&lt;211&gt; 130

&lt;212&gt; DNA

&lt;213&gt; Jurkat cell cDNA

&lt;400&gt; 6

```

caggatctta aaaatcccag ccatctaaat atgtttccca actccattaa gtaaggtaaa 60
ataatatttg tatttatgtt cagatgttga agctgtcatt ctcgaataaa actacacttt 120
agaaatggcg 130

```

&lt;210&gt; 7

&lt;211&gt; 361

&lt;212&gt; DNA

&lt;213&gt; Jurkat cell cDNA

&lt;400&gt; 7

```

gatctttcga ggccaggtgc ccaggctttt catcaagagc cccatttcca agtgctcagt 60
ancccttttt ggccagtgcn ccccaccac atgggacaag cgcaggtcca gtggcctccc 120
cagctgaccg caggcaggga acaaggcaga ccctagaggg ccaggccaca gcaggggctg 180
aggatgcctg gtgaatggat gcctgggaga atggatgccga gaattcacgc atgaggctct 240
gaacagggct gggaaaactt ccaaacgaag ggaagctcat gtcttgggtgc actttgtgat 300
gatgcttcaa cagcaggact gagatgggga catttacaat aaacagaaat gtatgggctc 360
g 361

```

&lt;210&gt; 8

&lt;211&gt; 176

&lt;212&gt; DNA

&lt;213&gt; Jurkat cell cDNA

&lt;400&gt; 8

```

ggatcttgca cgtatctgtt ttctccccc atgaactaga aaaccactta ctcccagaat 60
tcaggctcgtg cttgttagta ctatatacacc aagtcattc atttaatgat ccaaaaactgt 120
aatgttgac tgtattccaa ataaagggtg aaaacagaac caaagttata actccg      176

```

&lt;210&gt; 9

&lt;211&gt; 128

&lt;212&gt; DNA

&lt;213&gt; Jurkat cell cDNA

&lt;400&gt; 9

```

gatcaattct atgtctgact ttgaaattcc atttacaatg tagtatgttt tcaatgnnaa 60
accataaagt aacatccaag tgtttcatgg tttgttggga aggttaatttt aaaataaaac 120
aatttccg                                     128

```

&lt;210&gt; 10

&lt;211&gt; 138

&lt;212&gt; DNA

&lt;213&gt; Jurkat cell cDNA

&lt;400&gt; 10

```

gatcaagtca ctgcatgttg agaagtatag gtataacttg tgaccatata acagctcctt 60
tatttatgta gtttcttcac attttatgtg tacaatcaag catgcctgct gaccaaggcc 120
agaggtggag tggaagcg                                     138

```

&lt;210&gt; 11

&lt;211&gt; 271

&lt;212&gt; DNA

&lt;213&gt; Jurkat cell cDNA

&lt;400&gt; 11

```

gatctcaaca ttgttggttt cttttgtttt tcatttggtg caactttctt gaatttagaa 60
attacatctt tgcagttctg ttaggtgctc tgtaattaac ctgacttata tgtgaacaat 120
tttcatgaga cagtcatttt taactaatga agtgattctt tctcactact atctgtattg 180
tggaatgcac aaaattgtgt aggtgctgaa tgctgtaagg agtttaggtt gtatgaattc 240
tacaacccta taataaattt tactctatac g                                     271

```

&lt;210&gt; 12

&lt;211&gt; 186

&lt;212&gt; DNA

&lt;213&gt; Jurkat cell cDNA

&lt;400&gt; 12

```

gatccaaaac tatttggtan atgtatgggt agggtaaatac agtaagaggt gttatttgga 60
accttggttt ggacagttta ccagttgcct tttatcccaa agttgttgta acctnctgtg 120

```

atacgatgct tcaagagaaa atgcggttat aaaaaatggt tcagaattaa acttctaatt 180  
cattcg 186

<210> 13  
<211> 171  
<212> DNA  
<213> Jurkat cell cDNA

<400> 13  
ggatctgacc tccacggagc cgctgtcccc gccccctgc tcccgctgt ctgtcctgtc 60  
tgattctctt aggtgtcatg ttcttttttc tgtcttgtct tcaacttttt ttaaaactag 120  
attgctttga aaacatgact caataaaaagt ttcctttcaa tttaaacacc g 171

<210> 14  
<211> 151  
<212> DNA  
<213> T lymphocyte cDNA

<400> 14  
agctccagaa gcgcttggac aggctggagg agacagtcca ggccaagtag agccccacag 60  
ggcctccagc aggtgcagcc attcacaccc atccactcac ctccattcc cagccacgtg 120  
gcagagaaaa aaatcataat aaaatggctt t 151

<210> 15  
<211> 148  
<212> DNA  
<213> T lymphocyte cDNA

<400> 15  
ttnnngctacc tngtccaag tcttggcttn ccttttccan tcaacttact gtgcgctaag 60  
gggtggggtg aggggatgga gagggagggc tgccctaccat ggtctggggc ttgaggaaga 120  
tgagtttggt gatttaaata aagaattt 148

<210> 16  
<211> 194  
<212> DNA  
<213> T lymphocyte cDNA

<400> 16  
ctanttttaga tacgtccana nccaggaccg ctgagaactg ggacagtttc ctgggatgag 60  
tgccagcctg agcctgcatg gtgccgccga gcccggggtg gagggaggag ccaggcttcg 120  
cttcaaggcg gcctctacct tttctcagaa tggtttcctg atttgttcaa tgtgaaagt 180  
aaataaaatt tatg 194

<210> 17  
<211> 116  
<212> DNA  
<213> T lymphocyte cDNA

&lt;400&gt; 17

cactgtnnng aacggtcntg cnangtanna ngnccttctgc cnangnntct cncctncance 60  
 aanaggcanc tttcntannt atcctaacaa gccttggacc aaatggaaat aacagc 116

&lt;210&gt; 18

&lt;211&gt; 212

&lt;212&gt; DNA

&lt;213&gt; T lymphocyte cDNA

&lt;400&gt; 18

gctttattgg agagatacac acaaaggctg tccactcact tccataattt cttgatggac 60  
 atgtttttct cactgtcctt ctgcatgacc ttggctactg ccatctcaaa gtcctcctga 120  
 gtgacatgga ctgcccgttc tcgcagggca tacatgccag cttctgtgca cagcccttc 180  
 acttcaagcc cctgatgctc ctggcatgag ct 212

&lt;210&gt; 19

&lt;211&gt; 189

&lt;212&gt; DNA

&lt;213&gt; T lymphocyte cDNA

&lt;400&gt; 19

tgcatttatg gaaggcacat tacaggctctt tgtgggaaga aacagaaaga aatcacaaaa 60  
 gcaattaaga gagctcaaat aatgggggtt atgccagtta catacaagga tcctgcatat 120  
 ctcaaggacc ctaaagtttg taacatcaga tatcggaat aaattctatc acgttaccac 180  
 taataaact 189

&lt;210&gt; 20

&lt;211&gt; 219

&lt;212&gt; DNA

&lt;213&gt; T lymphocyte cDNA

&lt;400&gt; 20

antgnaggga aagctatgaa aggtgccggc ggatctacaa catggaaatg gctcgcaaga 60  
 tcaacttctt gatgcgaaaag aatcgggcag atccgtggca gggctgctga ggctgtggg 120  
 tgggacaccc agtgcgaaac cctcatccag tttctctctc atctcttttc tttgtacaat 180  
 cccatttctt attaccattc tctgcaataa actcaaac 219

&lt;210&gt; 21

&lt;211&gt; 285

&lt;212&gt; DNA

&lt;213&gt; T lymphocyte cDNA

&lt;400&gt; 21

agctcctccc tctggtggtg cttcctcagg gccaccatt gaagagggtg attaagccaa 60  
 ccaagtgtag atgtagcatt gttccacaca tttaaaacat ttgaaggacc taaattcgta 120  
 gcaaatcttg tggcagtttt aaaaagttaa gctgctatag taagttactg ggcatctca 180  
 atacttgaat atggaacata tgcacagggg aaggaaataa cattgcactt tataaacact 240



gtattgtaag tggaaaatgc aatgtcttaa ataaaactat ttaaa

285

<210> 22

<211> 195

<212> DNA

<213> T lymphocyte cDNA

<400> 22

ctanttttaga tncgtccaca gccaggaccg ctgagaactg ggacagtttc ctgggatgag 60  
tgccagcctg agcctgcatg gtgccgccga gcccggggtg gaggagggag ccaggcttcg 120  
cttcaaggcg gctctacct tttctcagaa tggtttcctg attgtgtcaa tgtgaaagt 180  
aaataaaatt tatgt 195

<210> 23

<211> 180

<212> DNA

<213> T lymphocyte cDNA

<400> 23

tttgtgccgt ctctccattc cactgcctgt tgcagagttt ttctgtaact aaggggggtg 60  
aggttattgt agacgttaga ttgcgggcac cgccagggat ttgcagcgc ttcagtgtac 120  
gtgttagaga atattggaaa agcgtctgtg agccccgtgc tgtatattgt aataaagtct 180

<210> 24

<211> 138

<212> DNA

<213> T lymphocyte cDNA

<400> 24

aggntctctg agcacttacc gggcgtgacc gtttcttagg tgtgagagg gctgtggctt 60  
ttgtgcagcg actatgttg tgtaggggt ggtgtggaga ttgttaatct tgtataaagc 120  
aattcaataa attgtttc 138

<210> 25

<211> 74

<212> DNA

<213> T lymphocyte cDNA

<400> 25

cgagnngcaa ncttctgagg cggtgtgtgc acaagccttt cagggggcac attcacaagt 60  
acctgttgtg tccc 74

<210> 26

<211> 119

<212> DNA

<213> T lymphocyte cDNA

<400> 26

tgtntccntg naagggncct tgcanagtaa tagggcttct gcctaagcct ctccctccaa 60  
 gccaataggc agctttctta actatcctaa caagccttgg accaaatgga aataaagct 119

<210> 27

<211> 253

<212> DNA

<213> T lymphocyte cDNA

<400> 27

gtgnncagct cttgncttgn ccaccgcccc gnnacangct gntcngnatn antatgaaga 60  
 gctcaatgtc tggcagggtca atgcttcccc gacacggatc acttttgtct gattccagcc 120  
 tgcttgcaac cctgggggtcc tcttggtccc tgctggcctg ccccttggga aggggcagtg 180  
 atgcctttga ggggaaggag gagcccctct ttctcccatg ctgcacttac tccttttctg 240  
 aataaaagtg ttt 253

<210> 28

<211> 344

<212> DNA

<213> T lymphocyte cDNA

<400> 28

cgagtgtagc acaancatnc gacngggcgac ttcgccantn tcctcctttn tgggaacanc 60  
 aanatacann ctccatttct ggagtcnggg tcttccgaag ccaggagctt gcctttccgc 120  
 tgagtcana ttggcagggtg gactacgagt catacacatg gcggaaactg gatcctggca 180  
 gtgaggagac ccagacgctg gttcgagagt acttttcctg ggagggggcc ttccagcatg 240  
 tgggcaaaagc cttcaatcag ggcaagatct tcaagtgaac atctcttgcc atcacctagc 300  
 tgctgacacc tgcccttcag ggagatgggg gtcattaaag gaaa 344

<210> 29

<211> 456

<212> DNA

<213> T lymphocyte cDNA

<400> 29

agtgtntgcc cagggctctg atgtgtcnct canagcttgn nnagcctgac acagctgtct 60  
 tgtgaggagc tgagatgcag gatttcttca cgcctcnct ttgtgacttc aanagcctct 120  
 ggcattctct tctgcaaagg cacctgaatg tgtctgcgtc cctgttagcn taatgtgagg 180  
 aggtggagag acagcccacc cntgtgtcca ctgtgacccc tgttcccatg ctgacctgtg 240  
 tttctcccc agtcattctt cttgttccag agaggtgggg ctggatgtct ccatctctgt 300  
 ctcaacttta ngtgactga gctgcaactt cttacttccc tactganaat aagaatctga 360  
 atatacatth gttttcccaa atatttggca tgaaaagggt ntggataant taataagcca 420  
 ttcccgggat tttgggaaan caanttttac cttnnga 456

<210> 30

<211> 122

<212> DNA

<213> T lymphocyte cDNA

&lt;400&gt; 30

cgtggngctc aagtctttnan ctgcccnaag ggatcaaacc tttcnggcct gtnatgattc 60  
 tgaccatttg acttgannca cangtgaatc tttctcctgg tgactcaaat aaaagtataa 120  
 tt 122

&lt;210&gt; 31

&lt;211&gt; 320

&lt;212&gt; DNA

&lt;213&gt; T lymphocyte cDNA

&lt;400&gt; 31

aggnanagtc catggggctg ccaacttcag acgaacagaa gaaacaggag attctgaaga 60  
 agttcatgga tcaacatccg gagatggatt tttccaaggc taaattcaac tagcccctgt 120  
 tttttcctcc ctgaactctt ggggctgagc tgcaaccacc caactttctt tcccactctt 180  
 ctctgggact tgtgggcctc agggcttggg gcaggcatgg gactggccca ggcacacagg 240  
 tcccggggca tcaggagaaa ggctgggtct tgggaccttg tcctccccag ttggcctact 300  
 gttacacatt aaaacgattt 320

&lt;210&gt; 32

&lt;211&gt; 116

&lt;212&gt; DNA

&lt;213&gt; T lymphocyte cDNA

&lt;400&gt; 32

gtgggtccaa gtctttgttt gnnctaagat ttgtnnctc tcagacngtg taaaacaaaa 60  
 tttattcatg ttttctgcat attaaaaaat cttattgtac caactggtaa actatt 116

&lt;210&gt; 33

&lt;211&gt; 210

&lt;212&gt; DNA

&lt;213&gt; T lymphocyte cDNA

&lt;400&gt; 33

tgtctccagg atctcatgag ccgcnacgtg ttnagagggc cnnatcata cgggggagg 60  
 ntggggcaaa tcgccacctg tacctttcct ctggccctgc tgccccaca cccaactccg 120  
 anggccacg ctggggaaaag cggaagcgc tcgctccctt tccccatta gtgctctctc 180  
 tgcttgatc ccggcagaag ctatgaaagg 210

&lt;210&gt; 34

&lt;211&gt; 155

&lt;212&gt; DNA

&lt;213&gt; T lymphocyte cDNA

&lt;400&gt; 34

tancntgnta cactcgntaa agaagagcan gatcangcna ctatactana ngttagcatc 60  
 actaacgcc ncgcatgtgc atgaaacacc ttctctgnc gccnattcca natttacact 120  
 gggagagggt ccagcaactg aataaatacc tctta 155

<210> 35  
 <211> 19  
 <212> DNA  
 <213> 5' sequence for primer  
  
 <400> 35  
 ctctcaagga tctaccgct 19  
  
 <210> 36  
 <211> 20  
 <212> DNA  
 <213> 5' sequence for primer  
  
 <400> 36  
 cagggtagac gacgctacgc 20  
  
 <210> 37  
 <211> 20  
 <212> DNA  
 <213> 5' sequence for primer  
  
 <400> 37  
 taataccgcg ccacatagca 20  
  
 <210> 38  
 <211> 55  
 <212> DNA  
 <213> 1-base anchored oligo(dT) primer  
  
 <400> 38  
 acgtaatacg actcactata gggcgaattg ggtcgacttt tttttttttt ttttv 55  
  
 <210> 39  
 <211> 40  
 <212> DNA  
 <213> 2-base anchored oligo(dT) primer, RP5.0  
  
 <400> 39  
 ctctcaagga tcttaccgct tttttttttt ttttttttat 40  
  
 <210> 40  
 <211> 40  
 <212> DNA  
 <213> 2-base anchored oligo(dT) primer, RP6.0  
  
 <400> 40  
 taataccgcg ccacatagca tttttttttt ttttttttcg 40

<210> 41  
<211> 40  
<212> DNA  
<213> 2-base anchored oligo(dT) primer, RP9.2

<400> 41  
cagggtagac gacgctacgc tttttttttt ttttttttga 40

<210> 42  
<211> 25  
<212> DNA  
<213> adapter oligonucleotide A1

<400> 42  
tagcgtccgg cgcagcgacg gccag 25

<210> 43  
<211> 29  
<212> DNA  
<213> adapter oligonucleotide A2


<400> 43  
gatcctggcc gtcggctgtc tgcggcgc 29

<210> 44  
<211> 40  
<212> DNA  
<213> PCR primer

<400> 44  
tgaagccgag acgtcggteg tttttttttt ttttttttvn 40

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/09761

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC(6) : C07H 21/04; C12N 15/00; C12Q 1/02, 1/68 US CL : 435/6, 29, 320.1, 325; 536/24.3, 23.5 According to International Patent Classification (IPC) or to both national classification and IPC																							
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) U.S. : 435/6, 29, 320.1, 325; 536/24.3, 23.5 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) APS DIALOG MEDLINE EMBASE BIOSIS LIFESCI																							
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>																							
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																					
Y	WO 97/05286 A1 (YALE UNIVERSITY) 13 February 1997, see entire document.	1-32																					
Y	GROSSMAN et al. SHORT ANALYTICAL REVIEW. From HIV Infection to AIDS: Are the Manifestations of Effective Immune Resistance Misinterpreted? Clinical Immunology And Immunopathology. 01 November 1993, Vol. 69, No. 2, pages 123-135, see entire document.	1-32																					
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.																							
<table border="0"> <tr> <td>* Special categories of cited documents:</td> <td>* T</td> <td>later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>* A</td> <td>document defining the general state of the art which is not considered to be of particular relevance</td> <td>* X</td> </tr> <tr> <td>* E</td> <td>earlier document published on or after the international filing date</td> <td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>* L</td> <td>document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>* Y</td> </tr> <tr> <td>* O</td> <td>document referring to an oral disclosure, use, exhibition or other means</td> <td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>* P</td> <td>document published prior to the international filing date but later than the priority date claimed</td> <td>* A</td> </tr> <tr> <td></td> <td></td> <td>document member of the same patent family</td> </tr> </table>			* Special categories of cited documents:	* T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	* A	document defining the general state of the art which is not considered to be of particular relevance	* X	* E	earlier document published on or after the international filing date	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	* L	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	* Y	* O	document referring to an oral disclosure, use, exhibition or other means	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	* P	document published prior to the international filing date but later than the priority date claimed	* A			document member of the same patent family
* Special categories of cited documents:	* T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																					
* A	document defining the general state of the art which is not considered to be of particular relevance	* X																					
* E	earlier document published on or after the international filing date	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																					
* L	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	* Y																					
* O	document referring to an oral disclosure, use, exhibition or other means	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																					
* P	document published prior to the international filing date but later than the priority date claimed	* A																					
		document member of the same patent family																					
Date of the actual completion of the international search 13 AUGUST 1999		Date of mailing of the international search report <b>13 SEP 1999</b>																					
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer  PATRICK J. NOLAN Telephone No. (703) 308-0196																					